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Abstract 
 With the number of ischemia reperfusion (I/R) injuries on the rise, and a lack of 
pharmacological intervention aimed at reducing free radical damage associated with I/R, 
we have developed 30 indole phenolic antioxidants that were synthesized by click 
chemistry to couple our indole with a phenolic or anisole derivative. The total antioxidant 
activity of the analogues was tested in vitro using the ferric thiocyanate lipid emulsion 
method. Compounds containing hydroxyl or methoxy aromatics at the 3 or 4 position on 
the aromatic coupled to the indole exhibited increased antioxidant scavenging. 4-
methoxyindole derivatives (8a-e) exhibited increased scavenging (p < 0.05) compared to 
the known antioxidant butylated hydroxyanisole (BHA). 
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Chapter 1 Introduction: 
 Ischemia/reperfusion (I/R) injury constitutes one of the most common 
pathophysiological responses encountered during surgical procedures and in diseased 
states such as: cardiac arrest, stroke, organ procurement, organ transplantation, aneurysm 
and arterial injury.1-10 The subsequent damage and cell death in response to reperfusion is 
unavoidable and can produce additional complications both localized and systemic 
including: necrosis, edema, respiratory distress syndrome and organ dysfunction.11 With 
the number one and four leading causes of death in the United States, according to the 
CDC being heart disease and cerebrovascular disease, and their high association with I/R 
injury; there is a need for pharmacological intervention with antioxidant therapy.12  
 Primary literature suggests the role reactive oxygen and nitrogen species 
(superoxide (O2.-), hydroxyl radical (.OH), hydrogen peroxide (H2O2), nitric oxide radical 
(.NO) and peroxynitrite (-ONOO)) (RONS) and inflammatory leukocytes play in I/R 
injuries.13 Most notably, RONS act as secondary messengers and play an important role 
in the regulation of apoptosis.14 As such, administration of antioxidants that inhibit 
reperfusion induced cellular damage and death is of therapeutic importance. The use of 
endogenous antioxidant therapeutics such as melatonin has provided crucial preliminary 
data on its ability to directly scavenge RONS and have a significant protective effect 
following I/R injury.9,15 Likewise, phenolic compounds such as resveratrol, butylated 
hydroxyl anisole (BHA) and polyphenols isolated from berries, vegetables and other food 
sources provide an additional source of antioxidants that can be utilized for therapeutic 
purposes (chart 1.1).16-20  
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Chart 1.1. Common antioxidants; melatonin (A), curcumin (B), resveratrol (C), butylated 
hydroxyanisole (D).  
 
 
1.1 Ischemia and the physiological response: 
 Ischemia is a complex physiological response caused by reduction and or 
stoppage of oxygen (hypoxia) and other vital nutrients to cells.9 Under normal aerobic 
conditions, oxygen (O2) is utilized in concert with glucose in glycolysis to produce 
energy for the cell in the form of adenosine triphosphate (ATP).21 The end product of 
glycolysis is pyruvate which can then be utilized in the citric acid cycle (TCA), 
essentially re-oxidizing nicotinamide adenine dinucleotide (NAD+) to NADH (figure 
1.1). Each step in aerobic respiration transfers electrons in a sequential step-down, of 
energy producing reactions within the mitochondrial electron transport chain (METC), 
which provide ATP in response to the energy demands of the cell (figure 1.2).21  
 
     
3 
 
 
Figure 1.1. Normal aerobic respiration maintains a fine equilibrium between O2 
consumption, glycolysis, ATP production, TCA and re-oxidation of NAD+ to NADH, 
while keeping reactive oxygen and nitrogen species (RONS) under control with free 
radical scavengers (gray circle). 
 
 
Figure 1.2. In METC cycling, in situ generated free radicals are detoxified by free radical 
scavengers like superoxide dismutase and converted to less harmful by-products. 
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 Upon marked decrease or halting of blood flow to the cell, a number of changes 
occur intracellularly. First, a drop in O2 causes a depletion of ATP stores within the cell 
leading to energy production via anaerobic respiration instead of aerobic respiration. 
Second, within the TCA under anaerobic conditions, re-oxidation of NAD+ to NADH is 
drastically reduced, lactate builds in excess, damage to mitochondrial free radical 
scavenging enzymes increases, and electron leaking from the METC begins generating 
excess reactive oxygen and nitrogen species (RONS) (figure 1.3).7,21,22 Under aerobic 
conditions xanthine dehydrogenase oxidizes hypoxanthine to uric acid using NAD+ as an 
electron acceptor forming NADH.23 During anaerobic metabolism, xanthine 
dehydrogenase is converted to xanthine oxidase, which has detrimental effects during the 
reperfusion phase as will be discussed later.7,23  
It is particularly important to mention ischemia related to the brain. RONS 
generation within the brain is markedly increased during ischemia as high iron 
concentrations in brain tissue lead to a greater production of the hydroxyl radical via the 
Fenton reaction (scheme 1.1).21,24 Furthermore, brain ischemia exacerbates neuronal 
death and the modulation of cellular functions of astrocytes and microglia that can lead to 
neurodegenerative diseases, leading to systemic pathologies.14  
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Figure 1.3. Ischemia and anaerobic respiration causes a depletion of O2, ATP, and ADP 
levels. TCA re-oxidation of NAD+ to NADH decreases with an increase in lactate. Free 
radical scavengers are damaged or used up, resulting in the generation of RONS and the 
beginning of cellular damage. 
 
 
 
 
 
Scheme 1.1. The Haber-Weiss (reaction 1) and Fenton (reaction 2) generates the highly 
reactive hydroxyl radical via the reduction of Fe3+ by the superoxide radical (reaction 1), 
and, oxidation of Fe2+ by H2O2 (reaction 2). 
 
 
 
1.2 Reperfusion and the physiological response: 
Reperfusion is the return of blood flow, O2 and nutrients following ischemia 
induced from shock, cardiac arrest, hemorrhage, vascular, hepatic and other surgeries.1,2,6-
10,25 The reperfusion stage can be broken up into two phases. First, initial return of blood 
flow to ischemic tissue results in the return of aerobic respiration. With the depletion of 
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NADH and antioxidant capabilities of the cell drastically decreased, electron transfer to 
O2 due to leaks in METC generates a relatively quick increase in the superoxide radical 
further overwhelming cellular RONS defenses.21,22,26 Oxidation of the mitochondrial 
membrane increases and cellular processes are further disrupted.  
 The second phase of reperfusion involves neutrophil infiltration, histamine release 
and the inflammatory response.2,5,27 Due to mitochondrial damage, the second phase of 
reperfusion results in high levels of apoptosis, leading to large increases in cellular debris 
and a further increase in inflammation.2,5,21,27 Administration of RONS scavenging 
compounds, particularly melatonin, has drastically decreased apoptosis, RONS and 
inflammation due to ischemia/reperfusion injuries. 
 
 
1.3 Melatonin and indoles as pharmacological agents: 
Melatonin is a hormone that is produced by the pineal gland and in the digestive 
tract.28 Its main function is in the regulation of circadian rhythms with peak blood plasma 
levels reached at night. Recently, melatonin has been identified as a potent antioxidant 
that is capable of crossing the blood brain barrier and scavenging RONS in both fatty and 
aqueous environments.14 The unique lipophilic and hydrophilic nature of melatonin not 
only provides the ability to cross the blood brain barrier, but also allows it to prevent 
oxidative stress in lipid membranes, and aqueous environments including, but not limited 
to: blood plasma, lysosomes and cytoplasm.14 As such, the free radical scavenging 
abilities and reduction of oxidative stress due to melatonin are considered superior to 
many common antioxidants, including vitamin C, glutathione and mannitol. Melatonin is 
capable of detoxifying two (.OH) radicals without begetting radicals. Simply put, 
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melatonin is a ‘suicidal antioxidant’, irreversibly detoxifying radicals without recycling 
of the molecule and propagation of other radicals.2   
Studies involving the use of melatonin related to I/R injuries have proved 
promising.2,4,5 Melatonin was found to directly scavenge RONS in vitro and in vivo by 
inhibiting lipid peroxidation and preventing DNA degradation.14,29 Administration of 
melatonin following surgery reduced morbidity and mortality following post-surgical 
induced oxidative stress, and reduced cytokines and nitrate/nitrite levels significantly.14 
More importantly, melatonin significantly reduced I/R injuries in the brain where as 
much as 20 % of total body oxygen is consumed.30 This is significant because the high 
oxygen consumption in the brain makes it more susceptible to RONS and oxidative 
damage.   
 With regards to cardiac protection, melatonin reduced cellular damage and 
exhibited antiapoptotic properties during I/R injuries. Furthermore, it has been implicated 
in the prevention of hypertension; presumably by inhibiting lipid oxidation in arteries and 
veins and reducing the build-ups of plaques seen in arteriosclerosis.14  
Additionally, melatonin has been found to bind to calcium binding proteins like 
calmodulin.30 It is well known that calmodulin binds to the small conductance calcium 
activated potassium channel (SK)31, and melatonin’s interaction not only with calmodulin 
but possibly SK channels can either downregulate or upregulate SK channel activity. SK 
channels are intrinsically tied to sympathetic nerve activity which is directly related to 
hypertension. It is therefore possible, that in addition to reducing oxidative stress in 
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cardiac I/R injuries, melatonin also provides slight regulation on sympathetic nerve 
activity, aiding in cardioprotective effects. 
 Despite the seemingly endless positives associated with melatonin treatment in 
I/R injuries, the use of melatonin as a therapeutic antioxidant for diseases associated with 
I/R have limitations. First, melatonin has a high first pass metabolism with a blood 
plasma half-life of roughly twenty minutes.30 Even though, melatonin has better 
antioxidant capabilities than most classical antioxidants, the quick metabolism of 
melatonin make it less viable for treating I/R injuries.14 To address the drawbacks of 
melatonin on the absorption, distribution, metabolism and excretion (ADME), analogues 
have been designed that retain the indole moiety and give roughly the same distribution 
as melatonin, but have a longer half-life.  
 Structure activity relationships (SAR) on the analogues identified a number of 
functional groups that provide the antioxidant potency seen with melatonin. The methoxy 
group on the indole ring was important, but not completely necessary for activity.13,14 
Conversion of the methoxy group to the hydroxyl group was actually found to increase 
the amount of hydroxyl radical production, but hydroxyl coupled with the N-acyl group 
showed improved potency compared with melatonin.14,29 Bi and colleagues also 
confirmed the pharmacaphore of the 5-methoxy functional group on the indole ring as 
being significant for potency.  
To this end, significant research has been devoted to the synthesis of indole 
derivatives and their use as pharmacological agents. Synthetically, indole containing 
structures present a unique and chemically tunable backbone that can give rise to 
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numerous and sometimes dual acting lead compounds for various diseases and conditions 
including: anti-inflammatory, antioxidant, anti-cancer, cardio and neuroprotective agents. 
As anti-inflammatory agents, indole backbones have been utilized in two well-
known non-steroidal anti-inflammatory drugs (NSAID) namely, Indomethacin and 
Acemetacin (chart 1.2). Indomethacin and Acemetacin have been extensively studied as 
NSAIDs, yet SAR studies for the indole class of NSAIDs has been lacking. With the 
discovery of indoles as efficient scavengers of free radicals, the anti-inflammatory 
properties of indoles were hypothesized to be attributed to the above observation. 
Indomethacin and Acemetacin were found to be effective scavengers of RONS, reducing 
neutrophil infiltration, histamine release and apoptosis which may contribute to their anti-
inflammatory activity.32,33  
 
Chart 1.2. NSAIDs Indomethacin (left), Acemetacin (right). 
Likewise, transient brain ischemia has long been known to produce ROS that lead 
to neuron death post-ischemia. Indomethacin was found to rescue neurons during brain 
ischemia and also inhibit COX1 and COX2 isoforms, drastically reducing oxidative 
stress, DNA oxidation, and cellular death following reperfusion.34 Despite its excellent 
capabilities as an NSAID, Indomethacine is not well tolerated in the gastrointestinal tract, 
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and analogues have been developed that still possess the NSAID activity with decreased 
side effects.  
As neuroprotective agents, indole derivatives are capable of detoxifying free 
radicals associated with brain ischemia injuries and preventing the drastic and detrimental 
death of neurons in the brain. Carvedilol and 1,2,3,4-tetrahydro-?-carboline derivatives 
show potent antioxidant scavenging in addition to exhibiting neuroprotective effects 
(chart 1.3).35-40 Additionally, Biradar and colleagues synthesized 2,5-disbubstituted 
indoles via a Knoevenagel condensation that were potent scavengers of free radicals 
(chart 1.4).33 
 
Chart 1.3. Indole derivatives Carvedilol (left), 1,2,3,4-tetrahydro-?-carboline (right). 
 
Chart 1.4. 6-chloro-10-phenyl-9,10-dihydropyrazolo[3,4-b]carbazol-3(2H)-one as an 
antioxidant and cytotoxic agent. 
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 As cardioprotective agents, certain indole containing compounds have been found 
to prevent lipid peroxidation, especially LDL, which is thought to be a major mechanism 
in the development of arteriosclerosis. Andreadou and colleagues specifically examined 
the antioxidant activity of an indole containing compound C6458 (chart 1.5) and found it 
to be an efficient scavenger of the hydroxyl radical. Additionally, C6458 is protective 
against myocardium injury from I/R and reduced infarct size in rabbits. Presumably this 
works by decreasing lipid peroxidation due to free radicals evident by the reduction in 
malondialdehyde levels, a well-known marker of oxidative stress.41 
 Similarly, Stobadine was found to not only reduce ROS, and diminish impairment 
of myocardium muscle from oxidative stress, but also possessed neuroprotective effects 
via a similar free radical scavenging mechanism as C6458. Stobadine, like melatonin, has 
similar lipophilic and hydrophilic characteristics that make it a suitable candidate for both 
aqueous and lipid environments. Pharmacokinetically, Stobadine is readily absorbed by 
the gastrointestinal tract, may be administered by IV and can easily penetrate the blood 
brain barrier. Slightly different from C6458, Stobadine has been found to more 
effectively scavenge lipid radicals during the propagation stage rather than scavenging 
during the initiation stage. This prevention of LDL oxidation is thought to directly 
correlate to the cardioprotective effects exhibited by Stobadine.42 
 
Chart 1.5. Cardioprotective indole derivatives Stobadine (left), C6458 (right). 
     
12 
 
 
1.4 Coupling of indoles with known compounds for use as 
treatment of I/R: 
 With the identification of melatonin as a possible lead, manipulation of the indole 
ring structure from that of melatonin has been found to lengthen metabolism time, and 
increase antioxidant potency. While some research groups have focused on melatonin 
analogues alone (chart 1.6), a common and more popular method is coupling either 
melatonin or an indole variant with a known antioxidant or anti-inflammatory compound. 
Bi and colleagues have successfully synthesized a series of melatonin analogues with 
different anti-inflammatory/antioxidant properties that reduce cellular damage associated 
with I/R injuries.13,36-38,43 
 
Chart 1.6. Melatonin analogues with variations on the indole ring, and amine chain. 
 
Two well-known derivatives of melatonin-related compounds coupled with an 
antioxidant include DTBHB and GWC20. Both were found to inhibit free radical induced 
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LDL oxidation more effectively compared to melatonin (chart 1.7).29 DTBHB contains 
di-tert-butyl-4-hydroxybenzamide (BHB) another well-known variant of the common 
food antioxidant BHA.44 Likewise, GWC20 contains the attached anisole derivative, also 
a variant of BHA.  
 
Chart 1.7. Two melatonin-related compounds with increased activity towards the 
reduction of LDL oxidation compared with melatonin. 
 
Continuing with this trend, antioxidant chemistry has further expanded to include 
retinoid-related compounds and the triazole moiety.29 Retinoid compounds provide 
another exogenous source of antioxidants that have been found to regulate epithelial 
cellular growth and provide lipid protection against oxidative damage. Coupling of indole 
??????-lipoic acid derivatives showed reduction in free radical damage in rat liver (chart 
1.8).29 
 
Chart 1.8. Chemical structures ??? ??????????-lipoic acid antioxidant derivatives. 
 
 Introduction of a triazole moiety was found to reduce reactive oxygen species in 
vitro (chart 1.9). Compounds tested by Andreadou and colleagues all showed significant 
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activity dependent on the attachment point for the triazole functional group. Additionally, 
cardioprotective effects were seen with triazole containing indoles by the reduction of 
malondialdehyde in rabbits during I/R injuries.29 
 
 
Chart 1.9. Chemical structure of a melatonin analogue containing a triazole moiety. 
 
1.5 Problem Statement: 
 As discussed above, a wide array of compounds can be coupled with melatonin 
and indole based backbones to tailor new pharmaceutical agents possessing anti-
inflammatory, antioxidant, cardioprotective or dual acting effects. The degree of variation 
seen on new indole or melatonin based compounds is only limited by creativity and the 
desire to produce new, more effective compounds falling under different classifications 
for their therapeutic use. To this end, we sought to couple the intrinsic antioxidant 
capabilities of melatonin and indole derivatives with phenolic/anisole derivatives to 
achieve extremely potent antioxidants for the treatment of I/R injuries.  
Melatonin and melatonin analogues have been shown to act synergistically with 
the native antioxidant defense system, which includes superoxide dismutase (SOD), 
vitamin C, vitamin E, glutathione, mannitol, etc. to mitigate oxidative stress and 
damage.2,8,23 Using this knowledge, we designed thirty compounds based on a strategy of 
coupling structural indole analogues of melatonin via a click reaction with phenols or 
anisoles. Structurally speaking, this approach gave three moieties capable of scavenging 
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free radicals; the indole moiety, the triazole moiety and the phenolic/anisole moiety with 
the added possibility of cardioprotective effects from the triazole moiety. These 
compounds were tested for their total antioxidant capabilities as will be discussed later. 
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Chapter 2 Results and Discussion: 
 
2.1 Synthesis: 
 
Scheme 2.1. Reagents and conditions: (i) (1) DMF, POCl3 0 °C, 30 min. 40 °C 1 h., (2) 
NaOH, reflux 1 h.; (ii) NH4OAc, CH3NO2, reflux 1 h.; (iii) (1) LiAlH4, THF, reflux 1 h., 
(2) Rochelle’s salts, ether, 12 h.; (iv) (a) TfN3, CuSO4(cat), K2CO3, 2:1 MeOH:H2O, (b) 
TfN3, ZnCl2(cat), Et3N, 3:7 H2O:acetonitrile, 5 min. RT. 
 
 Starting with 4-methoxyindole, a Vilsmeier-Haack reaction converted the indole 
to the desired indole-3-carboxaldehyde 1 that subsequently underwent a Henry reaction 
to afford the corresponding indole-nitroolefins 2a-e. After reduction with lithium 
aluminum hydride the desired tryptamines 3a-e were afforded in relatively high yield. 
Conversion of the tryptamine amino group to the corresponding azides 4a-f followed one 
of two routes. The first route involved solubilizing the desired tryptamine in a 2:1 
mixture of methanol:water with a catalytic amount of copper (II) sulfate and potassium 
carbonate. Freshly prepared triflic azide in dichloromethane was added and the 
conversion time, anywhere between 2-24 hours, depended on the substituent off the 
indole ring. The conversion of serotonin hydrochloride required an alternative approach.
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 Serotonin hydrochloride is unstable in aqueous base and decomposed at an 
accelerated rate when attempting to convert the amino group to azide. Serotonin in itself 
degrades quickly when exposed to light and moisture, so a quick conversion method from 
amine to azide needed to be employed. Previously, dopamine hydrochloride had been 
converted successfully to the desired azide utilizing an alternative method. Using 
serotonin hydrochloride treating it with a 3:7 solution of acetonitrile:water with 
triethylamine and a catalytic amount of zinc (II) chloride, and triflic azide, the serotonin 
amine was converted to the desired azide 4d in five minutes. It should be noted that once 
converted to the azide, serotonin continues to degrade at an appreciable rate, requiring a 
quick workup and purification. 
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Scheme 2.2. Reagents and conditions: (i) CuI, 2:1 PEG-400:DMF, RT 12 h. 
 
 
Table 2.1 Indole/Phenolic prepared analogues via click reactions. 
Compound R1 R2 R3 R4 R5 
5a H F OCH3 H H 
5b H F H OCH3 H 
5c H F H OH H 
5d H F H OCH3 OCH3 
5e H F F H H 
6a H OH H OCH3 OCH3 
6b H OH H OCH3 H 
6c H OH OCH3 H H 
6d H OH F H H 
6e H OH H OH H 
7a H OCH3 H OCH3 OCH3 
7b H OCH3 H OCH3 H 
7c H OCH3 H OH H 
7d H OCH3 OCH3 H H 
7e H OCH3 F H H 
8a OCH3 H F H H 
8b OCH3 H OCH3 H H 
8c OCH3 H H OCH3 OCH3 
8d OCH3 H H OCH3 H 
8e OCH3 H H OH H 
9a H Br H OCH3 H 
9b H Br OCH3 H H 
9c H Br H OCH3 OCH3 
9d H Br F H H 
9e H Br H OH H 
10a H H OCH3 H H 
10b H H H OH H 
10c H H H OCH3 OCH3 
10d H H F H H 
10e H H H OCH3 H 
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 With the azides in hand, we explored different click reaction conditions to couple 
the indoles with aromatic alkynes. Attempts utilizing various solvents in a 1:1 ratio like; 
MeOH:H2O, EtOH:H2O, t-butanol:H2O with copper (II) sulfate and sodium ascorbate, 
proved fruitless. Likewise, using copper (I) with acetonitrile and DMF as solvents also 
gave very low yields or no product. Reviewing the literature involving click reactions 
with indoles, we were able to find one account reporting similar difficulties involving 
indoles and click reactions. Their solution was using copper (I) and PEG-400 as the 
solvent. 45 Utilizing this solvent system, with a little experimentation, we finally achieved 
the optimal solvent system (2:1 PEG-400:DMF) capable  of solubilizing the indole and 
aromatic alkyne, to carry out the desired click reaction affording analogues 5-10.  
It is interesting to note that certain click coupling reactions of indole with 
aromatic alkyne resulted in a chelation effect with the copper in solution. This 
phenomenon was evident by the emulsion formed upon aqueous workup and low yields. 
To reduce the emulsions formed and free the desired product from copper, certain click 
products having the above observations were stirred with disodium EDTA overnight in a 
1:1 mixture of ethyl acetate:water, followed by an aqueous work-up and purification.  
 
2.2 Total Antioxidant Scavenging: 
 To test the antioxidant capabilities of the newly synthesized compounds, total 
antioxidant scavenging using the iron thiocyanate method with linoleic acid emulsion 
was employed at 37 ?C. Linoleic acid naturally oxidizes forming lipid peroxides that, 
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when treated with iron (II), oxidize iron (II) to iron (III) to form complexes with 
thiocyanate giving a red hue with a maximum absorption at 500 nm. Incubation of the 
linoleic acid emulsion with antioxidants reduces the degree of lipid peroxidation and 
subsequently reduces the formation of the iron (III) thiocyanate complex as measured by 
UV-VIS spectroscopy. 
Originally, the goal of this strategy was to compare the new indole analogue 
antioxidants with the parent antioxidant, melatonin. Upon running several trials with 
melatonin, it was apparent that the results of the total antioxidant capability of melatonin 
varied. Literature searches explained the discrepancy. Melatonin has been documented as 
having the capabilities of chelating transition metals; copper and iron to name a few, and 
our subsequent hypothesis for the varied results during the total antioxidant tests were 
confirmed based on this characteristic.46,47 
In order for the test to have validity, we needed another well-known antioxidant 
as a comparison and therefore attempted a trial with vitamin C. Vitamin C, also like 
melatonin proved to be a poor standard as vitamin C is used as a reducing agent in click 
reactions, reducing copper (II) to copper (I).48 Likewise, once iron (II) and thiocyanate 
were added to the linoleic acid emulsion with vitamin C, any iron (III) generated was 
quickly reduced back to iron (II) and gave 100 % inhibition.  
Finally, butylated hydroxyanisole (BHA) was tested and gave consistent results 
with the total antioxidant method through a number of trials. BHA is a well-known 
antioxidant that is used in foods and food packaging.49 The antioxidant capabilities of 
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BHA are quite remarkable and provided a reasonable comparison for our newly 
synthesized analogues. 
With our suitable standard identified, we turned towards the analogues. Original 
protocol from the literature indicated solubilizing the desired antioxidants in a phosphate 
buffer with subsequent addition of this solution to a linoleic acid emulsion in the same 
buffer. This however was impractical as almost all compounds were virtually insoluble in 
aqueous solutions. To increase solubility, samples were dissolved in DMSO and added to 
a linoleic acid emulsion in phosphate buffer. While this increased solubility, certain 
compounds were observed to be slightly less soluble than others, indicating that 2nd 
generation compounds should be prepared with the goal of increasing aqueous solubility.  
Once incubated at physiological temperature for 24 hours, the solutions were 
measured for their ability to inhibit lipid peroxidation. A number of compounds showed 
comparable antioxidant capabilities to BHA with a few showing significant improvement 
compared to BHA; namely 8a-e. From the results, the following properties of the 
possible pharmacophore for antioxidant capabilities were identified.  
Of the phenolic analogues that were added to the indoles via click reaction, the 3-
methoxy, 4-methoxy and 3-hydroxyl aromatic rings proved the most effective. This is 
consistent with literature data involving anisoles, phenols and polyphenols as 
antioxidants.50-52 Secondly, the indole substituents were also crucial to the antioxidant 
activity. Serotonin analogues containing the 3-methoxy and 4-methoxy coupled aromatics 
(6b, 6c, 6e) had comparable inhibition of lipid peroxidation to that seen with BHA. This 
finding is consistent with melatonin SAR studies.14 The 5-bromo substituted indole, 
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coupled with 3-methoxy, 4-methoxy and 3-hydroxy aromatics (9a, 9b, 9e) also had 
comparable inhibition of lipid peroxidation to BHA. The 4-methoxy substituent however 
had a marked increase in inhibition of lipid peroxidation compared with BHA (figure 
2.7). Furthermore, all analogues containing the 4-methoxy substituent on the indole ring, 
regardless of the aromatic functional group that was coupled to it, showed an increase in 
inhibition of lipid peroxidation compared to similar indoles without the 4-methoxy 
functional group. This strongly suggests that the 4-methoxy functional group on the 
indole ring may add increased antioxidant potency especially in the prevention of lipid 
peroxidation.  
 Indole analogues containing the fluoro group at the 5 position on the indole (5a-e, 
figure 2.1) had very poor total antioxidant activity. It should be noted that the 5-
fluoroindoles once coupled with their corresponding aromatic phenol or anisole had very 
poor solubility and may not have been effective at scavenging free radicals under 
conditions in the test employed. 
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Figure 2.1. 4. Total antioxidant scavenging of 5-fluoroindole click products with 
corresponding phenol/anisole and standard deviation bars. The data are the average of 
triplicates. 
 
 Indole analogues having the bromine at the 5 position on the indole (9a-e, figure 
2.3) posessed similar antioxidant scavenging compared to BHA with analogue 9b having 
improved scavenging. 9b contains the aromatic anisole with the methoxy group at the 4 
position on the aromatic ring. As many SAR studies of melatonin and their analogues 
used for antioxidant purposes have indicated, the pyrrole has been observed to be 
important in forming a stable structure once the free radical has been neutrilized. Given 
the orientation of the pyrrole with regards to the 4-methoxyanisole moiety, electron 
delocalization from the methoxy group towards the para position could possibly activate 
the triazole towards detoxification of free radicals. Coupling this with the close proximity 
of the pyrrole and its use in forming cyclic structures after detoxification of radicals 
(figure 2.2), it seems resonable to propose such a hypothesis, however, metabolites would 
need to be identified to support this theory.  
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Figure 2.2. Cyclic-3-hydroxymelatonin 
 
Figure 2.3. 6. Total antioxidant scavenging of 5-bromoindole click products with 
corresponding phenol/anisole and standard deviation bars. The data are the average of 
triplicates. 
 
 The indole analogues containing the hydroxyl group at the 5 position on the 
indole (6a-e, figure 2.4) had comparable antioxidant scavenging relative to BHA with 6e 
having increased scavenging. 6e contains the phenol moiety at the 3 position on the 
aromatic ring relative to the connection of the triazole. Phenolic compounds such as 
resveratrol have been documented as detoxifying free radicals, and we hypothesize that 
the increased antioxidant capability may be due to the phenolic substituent connected to 
the indole. 
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Figure 2.4. 7. Total antioxidant scavenging of 5-hydroxyindole click products with 
corresponding phenol/anisole and standard deviation bars. The data are the average of 
triplicates. 
 
 Analogues containing the indole backbone and also the methoxy functional group 
at the 5 position on the indole (10a-e, 7a-e) had comparable antioxidant scavenging to 
BHA (figures 2.5 and 2.6). It is interesting to note that the 5-methoxyindole derivatives 
did not perform as well as literature had indicated based on the SAR studies involving 
melatonin. While the 5-methoxyindole derivatives were somewhat effective, noteable 
125 μmol, their effectiveness tailed off in the lower concentration range of 32 μmol 
(figure 2.6). 
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Figure 2.5. 8. Total antioxidant scavenging of indole click products with corresponding 
phenol/anisole and standard deviation bars. The data are the average of triplicates. 
 
 
 
Figure 2.6. 9. Total antioxidant scavenging of 5-methoxyindole click products with 
corresponding phenol/anisole and standard deviation bars. The data are the average of 
triplicates. 
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 The 4-methoxyindole containing analogues 8a-e all showed an increased ability to 
scavenge radicals compared to BHA (figure 2.7). As discussed earlier, the pyrrole has 
been identified as being crucial to radical detoxification. The 4-methoxy substituent on 
the indole ring through electron delocalization can make the pyrrole ring more electron 
rich, increasing the ability to react with free radicals produced from the lipid peroxidation 
(scheme 2.3). This hypothesis seems reasonable, and the 4-methoxy functional group on 
the indole backbone appears as though it may be more potent, at least at prevention of 
lipid oxidation compared to all other analogues tested.  
 
 
Scheme 2.3. Detoxification of free radicals with 4-methoxyindole analogues. 
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Figure 2.7. 10. Total antioxidant scavenging of 4-methoxyindole click products with 
corresponding phenol/anisole and standard deviation bars. The data are the average of 
triplicates. 
 
2.3 Conclusions and Future Work: 
Based on the preliminary results from the total antioxidant scavenging using the 
ferric thiocyanate method, a number of analogues possessed a marked improvement 
compared to the known antioxidant standard BHA. All 4-methoxyindole containing 
analogues 8a-e, and analogues 6e and 9b were capable of inhibiting lipid oxidation better 
than BHA, suggesting that the 4-methoxy substituent on the indole ring is crucial to the 
detoxification of radicals. Additionally, aromatic anisoles and phenols were identified 
across all synthesized analogues as having the greatest capability at preventing lipid 
oxidation, suggesting that anisoles and phenols also possess radical scavenging 
capabilities. To this end, 2nd generation analogues should, if possible contain the 4-
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methoxy substituent on the indole ring coupled to one or more anisoles or phenolic 
compounds.  
 Synthetically speaking, we began to explore new 2nd generation compounds 
containing di-phenolic and di-anisole containing aromatics coupled to the indole 
backbone via a double click reaction. However, the synthesis proved complicated as our 
first approach utilized tripropargylamine and the corresponding indole azide (scheme 
2.4). As experimentation proved, we had little control over the degree of substitution on 
the tripropargyl functional groups and therefore produced a poly substituted click 
analogue containing the indole azides.  
 
Scheme 2.4. Initial approach to synthesizing diphenolic indole antioxidants. 
We then explored conversion of the tryptamine to a di-substituted propargyl 
amine via a double nucleophilic substitution reaction (scheme 2.5). This reaction proved 
to only work for the tryptamine and resulted in numerous products that were unable to be 
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purified when working with substituted indoles. With the dipropargyl indole, we had to 
work out a new solvent system for the click reaction as the traditional solvent system 
employed from the 1st generation analogues, (2:1 DMF:PEG-400) did not produce the 
desired results. The final solvent system that appeared to give good yields was (2:1:1 
PEG-400:H2O:MeOH) followed by chelation of copper with EDTA. 
 
Scheme 2.5. Synthesis of diphenolic indole antioxidants via nucleophilic substitution 
with 2 eq. of propargyl bromide. 
 Due to the sensitive nature of substituted indoles in the presence of base, an 
alternative approach may need to be employed to couple the desired indole with aromatic 
anisoles or phenols. A common method used to synthesize tryptamines involves the use 
of oxalyl chloride followed by reaction with an amine and reduction of the ketone 
functional groups (scheme 2.6). This method seems to be a plausible solution to the 
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above problem noticed when using substituted indoles subjected to the conditions shown 
in scheme 6. 
 
Scheme 2.6. Proposed synthesis for diphenolic indole antioxidants. 
 Additionally, to get a better picture of how well the 1st generation analogues 
performed for antioxidant scavenging, it may be beneficial to subject the compounds to 
additional in vitro testing to more conclusively identify lead compounds. Furthermore, in 
vivo testing of 1st generation lead compounds would solidify their antioxidant scavenging 
capabilities in animal models and generate stronger evidence in the design of 2nd 
generation compounds.  
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Chapter 3 Experimental: 
 
3.1 Synthesis of starting materials: 
All starting materials and solvents were purchased from commercial sources unless 
otherwise stated. Thin layer chromatography (TLC) was performed using Sigma-Aldrich 
TLC plates 0.25 μm thickness. Flash chromatography was performed using Alfa Aesar 
silica gel, particle size 230-400 mesh. 1H, 19F and 13C NMR were recorded on a Varian 
UNITY INOVA instrument at 400 MHz and 100 MHz respectively. UV-vis spectra were 
recorded on a Perkin Elmer Lambda 35 UV/vis. 
 
4-Methoxyindole-3-carboxaldehyde (1) was synthesized according to a previously 
published procedure.53 Briefly, 1.42 g (9.65 mmol) 4-Methoxyindole was dissolved in 4.5 
mL (57.76 mmol) DMF and 1.9 mL (13.86 mmol) POCl3 added with stirring at 0 °C. The 
mixture was stirred for 30 min. at 0 °C and then at 40 °C for 1 h. 60 mL (2 M) NaOH was 
added with stirring over ice and the mixture heated at reflux for 1 h. The mixture was 
cooled and diluted with 60 mL of water and extracted with 3x 50 mL portions of ethyl 
acetate. The organic layers were combined, dried over Na2SO4, decanted and the solvent 
removed by rotary evaporation. The product, 4-Methoxyindole-3-carboxaldehyde was 
used without further purification. 
 
3.2 Synthesis of Indole nitro olefins: 
The different substituted indole nitro olefins compounds were synthesized according to a 
previously published procedure.54  
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(E)-5-methoxy-3-(2-nitrovinyl)-1H-indole (2a): 
 
2.0 g (11.42 mmol) 5-Methoxyindole-3-carboxaldehyde and 500 mg NH4OAc were 
added to 40 mL nitromethane and heated at reflux with stirring for 1 h. The solvent was 
removed by rotary evaporation and the product collected by vacuum filtration, washed 
with copious amounts of water and air dried overnight. The product, (E)-5-methoxy-3-(2-
nitrovinyl)-1H-indole was used without further purification. 
 
(E)-5-bromo-3-(2-nitrovinyl)-1H-indole (2b): 
 
1.48 g (6.6 mmol) 5-Bromoindole-3-carboxaldehyde and 400 mg NH4OAc were added to 
20 mL nitromethane and heated at reflux with stirring for 1 h. The solvent was removed 
by rotary evaporation and the product collected by vacuum filtration, washed with 
copious amounts of water and air dried overnight. The product, (E)-5-bromo-3-(2-
nitrovinyl)-1H-indole was used without further purification. 
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(E)-5-fluoro-3-(2-nitrovinyl)-1H-indole (2c): 
 
2.20 g (13.49 mmol) 5-Fluoroindole-3-carboxaldehyde and 900 mg NH4OAc were added 
to 40 mL nitromethane and heated at reflux with stirring for 1 h. The solvent was 
removed by rotary evaporation and the product collected by vacuum filtration, washed 
with copious amounts of water and air dried overnight. The product, (E)-5-fluoro-3-(2-
nitrovinyl)-1H-indole was used without further purification.  
 
(E)-3-(2-nitrovinyl)-1H-indole (2d): 
 
1.23 g (8.48 mmol) Indole-3-carboxaldehyde and 300 mg NH4OAc were added to 20 mL 
nitromethane and heated at reflux with stirring for 1 h. The solvent was removed by 
rotary evaporation and the product collected by vacuum filtration, washed with copious 
amounts of water and air dried overnight. The product, (E)-3-(2-nitrovinyl)-1H-indole 
was used without further purification. 
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(E)-4-methoxy-3-(2-nitrovinyl)-1H-indole (2e): 
 
1.0 g (5.71 mmol) 4-Methoxyindole-3-carboxaldehyde and 760 mg NH4OAc were added 
to 30 mL nitromethane and heated at reflux with stirring for 1 h. The solvent was 
removed by rotary evaporation and the product collected by vacuum filtration, washed 
with copious amounts of water and air dried overnight. The product, (E)-4-methoxy-3-(2-
nitrovinyl)-1H-indole was used in without further purification. 
 
3.3 Synthesis of Tryptamines: 
The conversion to tryptamines from the nitro olefin indoles were carried out following a 
previously published procedure.54 
 
5-Methoxytryptamine (3a): 
 
2.60 g (11.93 mmol) (E)-5-methoxy-3-(2-nitrovinyl)-1H-indole was dissolved in 20 mL 
anhydrous THF and added to a slurry of 3 g LiAlH4 in 40 mL anhydrous THF with 
stirring at 0 °C. The mixture was heated at reflux for 1 h. Excess LiAlH4 was quenched 
with water at 0 °C and 80 mL of saturated Rochelle’s salts and 100 mL ether was added. 
The mixture was stirred at room temperature overnight. The aqueous layer was removed 
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and the organic layer extracted with 3x 40 mL portions of 1M HCl. The acidic layers 
were combined and basified with KOH with stirring over ice. The basic solution was then 
extracted with 3x 40 mL portions of ether. The organic layers were combined, dried over 
Na2SO4, decanted and the solvent removed by rotary evaporation. The product, 5-
Methoxytryptamine was used without further purification.  
 
5-Bromotryptamine (3b): 
 
1.48 g (5.54 mmol) (E)-5-bromo-3-(2-nitrovinyl)-1H-indole was dissolved in 10 mL 
anhydrous THF and added to a slurry of 1.55 g LiAlH4 in 40 mL anhydrous THF with 
stirring at 0 °C. The mixture was heated at reflux for 1 h. Excess LiAlH4 was quenched 
with water at 0 °C and 80 mL of saturated Rochelle’s salts and 100 mL ether was added. 
The mixture was stirred at room temperature overnight. The aqueous layer was removed 
and the organic layer extracted with 3x 40 mL portions of 1M HCl. The acidic layers 
were combined and basified with KOH with stirring over ice. The basic solution was then 
extracted with 3x 40 mL portions of ether. The organic layers were combined, dried over 
Na2SO4, decanted and the solvent removed by rotary evaporation. The product, 5-
Bromotryptamine was used without further purification. 
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5-Fluorotryptamine (3c): 
 
2.71 g (13.15 mmol) (E)-5-fluoro-3-(2-nitrovinyl)-1H-indole was dissolved in 20 mL 
anhydrous THF and added to a slurry of 3.15 g LiAlH4 in 40 mL anhydrous THF with 
stirring at 0 °C. The mixture was heated at reflux for 1.5 h. Excess LiAlH4 was quenched 
with water at 0 °C and 80 mL of saturated Rochelle’s salts and 100 mL ether was added. 
The mixture was stirred at room temperature overnight. The aqueous layer was removed 
and the organic layer extracted with 3x 40 mL portions of 1M HCl. The acidic layers 
were combined and basified with KOH with stirring over ice. The basic solution was then 
extracted with 3x 40 mL portions of ether. The organic layers were combined, dried over 
Na2SO4, decanted and the solvent removed by rotary evaporation. The product, 5-
Fluorotryptamine was used without further purification. 
 
Tryptamine (3d): 
 
1.77 g (9.41 mmol) (E)-3-(2-nitrovinyl)-1H-indole was dissolved in 20 mL anhydrous 
THF and added to a suspension of 2.00 g LiAlH4 in 30 mL anhydrous THF with stirring 
at 0 °C. The mixture was heated at reflux for 1 h. Excess LiAlH4 was quenched with 
water at 0 °C and 80 mL of saturated Rochelle’s salts and 100 mL ether was added. The 
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mixture was stirred at room temperature overnight. The aqueous layer was removed and 
the organic layer extracted with 3x 40 mL portions of 1M HCl. The acidic layers were 
combined and basified with KOH with stirring over ice. The basic solution was then 
extracted with 3x 40 mL portions of ether. The organic layers were combined, dried over 
Na2SO4, decanted and the solvent removed by rotary evaporation. The product, 
Tryptamine was used without further purification. 
 
4-Methoxytryptamine (3e): 
 
2.57 g (11.79 mmol) (E)-4-methoxy-3-(2-nitrovinyl)-1H-indole was dissolved in 15 mL 
anhydrous THF and added to 2.74 g LiAlH4 suspended in 40 mL anhydrous THF with 
stirring at 0 °C. The mixture was heated at reflux for 1.5 h. Excess LiAlH4 was quenched 
with water at 0 °C and 80 mL of saturated Rochelle’s salts and 100 mL ether was added. 
The mixture was stirred at room temperature overnight. The aqueous layer was removed 
and the organic layer extracted with 3x 40 mL portions of 1M HCl. The acidic layers 
were combined and basified with KOH with stirring over ice. The basic solution was then 
extracted with 3x 40 mL portions of ether. The organic layers were combined, dried over 
Na2SO4, decanted and the solvent removed by rotary evaporation. The product, 4-
Methoxytryptamine was used without further purification. 
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3.4 Conversion of Tryptamines to Tryptamine azides: 
The conversion of Tryptamine, 4-Methoxytryptamine, 5-Methoxytryptamine, 5-
Bromotryptamine and 5-Fluorotryptamine to their corresponding azides were 
accomplished according to a previously published procedure. 55  
 
Preparation of Triflic azide: 
5.65 g (86.9 mmol) NaN3 was dissolved in 40 mL 1:1 CH2Cl2:H2O. 3 mL, (17.84 mmol) 
Triflic anhydride was added with stirring at 0 °C for 2 h. The organic layer was separated 
and the aqueous layer extracted with 20 mL CH2Cl2. The organic layers were combined 
and washed with 40 mL saturated Na2CO3. The Triflic azide in 40 mL CH2Cl2 was used 
without further purification.  
 
3-(2-azidoethyl)-5-methoxy-1H-indole (4a): 
 
2.18 g (11.47 mmol) 5-Methoxytryptamine was dissolved in 90 mL 2:1 MeOH:H2O and 
150 mg CuSO4 and 1.50 g K2CO3 added. The freshly prepared TfN3 in 40 mL CH2Cl2 
was added and the mixture stirred at room temperature overnight. The solvent was 
removed by rotary evaporation and the crude dissolved in 80 mL 1:1 EtOAc:H2O. The 
mixture was extracted with 2x 40 mL portions of EtOAc. The organic layers were 
combined, dried over Na2SO4, decanted and the solvent removed by rotary evaporation. 
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The crude was purified by flash column chromatography, eluting with 50:50 
EtOAc:Hexanes. The title compound was used immediately after purification. 
 
3-(2-azidoethyl)-5-bromo-1H-indole (4b): 
 
1.36 g (5.69 mmol) 5-Bromotryptamine was dissolved in 90 mL 2:1 MeOH:H2O and 100 
mg CuSO4 and 1.30 g K2CO3 added. The freshly prepared TfN3 in 40 mL CH2Cl2 was 
added and the mixture stirred at room temperature overnight. The solvent was removed 
by rotary evaporation and the crude dissolved in 80 mL 1:1 EtOAc:H2O. The mixture 
was extracted with 2x 40 mL portions of EtOAc. The organic layers were combined, 
dried over Na2SO4, decanted and the solvent removed by rotary evaporation. The crude 
was purified by flash column chromatography, eluting with 50:50 EtOAc:Hexanes. The 
title compound was used immediately after purification. 
 
3-(2-azidoethyl)-5-fluoro-1H-indole (4c): 
 
900 mg ( mmol) 5-Fluorotryptamine was dissolved in 90 mL 2:1 MeOH:H2O and 100 mg 
CuSO4 and 900 mg K2CO3 added. The freshly prepared TfN3 in 40 mL CH2Cl2 was 
added and the mixture stirred at room temperature overnight. The solvent was removed 
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by rotary evaporation and the crude dissolved in 80 mL 1:1 EtOAc:H2O. The mixture 
was extracted with 2x 40 mL portions of EtOAc. The organic layers were combined, 
dried over Na2SO4, decanted and the solvent removed by rotary evaporation. The crude 
was purified by flash column chromatography, eluting with 50:50 EtOAc:Hexanes. The 
title compound was used immediately after purification. 
 
3-(2-aminoethyl)-1H-indol-5-ol (4d): 
 
The conversion of serotonin hydrochloride to the corresponding azide was accomplished 
according to a previously published procedure with modifications.56 Briefly, 1.09 g (16.8 
mmol) NaN3, 2.30 mL (14.0 mmol) triflic anhydride was added to 15 mL of anhydrous 
acetonitrile with stirring at 0 °C. The mixture was stirred for 2 h. 2.05 g ( mmol) 
Serotonin hydrochloride, 160 mg ZnCl2 and 4.8 mL (36.6 mmol) Et3N dissolved in 30 
mL 3:7 H2O:acetonitrile was added and stirred for 5 minutes. The solvent was removed 
and the residue diluted with 40 mL of water. The mixture was extracted with 3x 40 mL 
portions of EtOAc. The organic layers were combined, dried over Na2SO4, decanted, and 
the solvent removed by rotary evaporation. The crude was purified by flash column 
chromatography, eluting with 50:50 EtOAc:Hexanes. The title compound was used 
immediately after purification. 
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3-(2-azidoethyl)-1H-indole (4e): 
 
1.29 g (8.06 mmol) Tryptamine was dissolved in 90 mL 2:1 MeOH:H2O and 100 mg 
CuSO4 and 1.30 g K2CO3 added. The freshly prepared TfN3 in 40 mL CH2Cl2 was added 
and the mixture stirred at room temperature overnight. The solvent was removed by 
rotary evaporation and the crude dissolved in 80 mL 1:1 EtOAc:H2O. The mixture was 
extracted with 2x 40 mL portions of EtOAc. The organic layers were combined, dried 
over Na2SO4, decanted and the solvent removed by rotary evaporation. The crude was 
purified by flash column chromatography, eluting with 50:50 EtOAc:Hexanes. The title 
compound was used immediately after purification.  
 
3-(2-azidoethyl)-4-methoxy-1H-indole (4f): 
 
1.91 g (10.05 mmol) 4-Methoxyindole was dissolved in 90 mL 2:1 MeOH:H2O and 190 
mg CuSO4 and 1.91 g K2CO3 added. The freshly prepared TfN3 in 40 mL CH2Cl2 was 
added and the mixture stirred at room temperature for 1.5 h. The solvent was removed by 
rotary evaporation and the crude dissolved in 80 mL 1:1 EtOAc:H2O. The mixture was 
extracted with 2x 40 mL portions of EtOAc. The organic layers were combined, dried 
over Na2SO4, decanted and the solvent removed by rotary evaporation. The crude was 
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purified by flash column chromatography, eluting with 50:50 EtOAc:Hexanes. The title 
compound was used immediately after purification. 
 
3.5 Synthesis of Melatonin/Phenolic compounds: 
5-fluoro-3-(2-(4-(4-methoxyphenyl)-1H-1,2,3-triazol-1-yl)ethyl)-1H-indole (5a): 
 
973 mg (4.82 mmol) 3-(2-azidoethyl)-5-fluoro-1H-indole was dissolved in 8 mL 2:1 
PEG-400:DMF and 1.15 g CuI and 0.685 mL (5.30 mmol) 4-Ethynylanisole added. The 
mixture was stirred at room temperature for 12 h. The mixture was diluted with 60 mL 
H2O and extracted with 3x 40 mL portions of ethyl acetate. The organic layers were 
combined, dried over Na2SO4, decanted and the solvent removed by rotary evaporation. 
The crude was purified by flash column chromatography, eluting with 70:30 ethyl 
acetate:hexanes to give 490 mg (30 % yield) of a light brown crystals.  1H NMR (CDCl3) 
?????????????????????????????J = 2.0 Hz, 2H), 7.40 (s, 1H), 7.23 (dd, J = 8.6 Hz, 4.4 Hz, 
1H), 7.14 (dd, J = 9.6 Hz, 2.1 Hz, 1H), 6.88 (m, 4H), 4.59 (t, J = 7 Hz, 2H), 3.78 (s, 3H), 
3.29 (t, J = 6.8 Hz, 2H); 13C NMR (CDCl3???????????????????????J = 235 Hz, 1C), 147.3, 
132.7, 127.09 (d, J = 9.1 Hz, 1C), 127.0, 124.6, 123.1, 119.4, 114.2, 112.18 (d, J = 9.1 
Hz, 1C), 110.96 (d, J = 4.6 Hz, 1C), 110.45 (d, J = 27.4 Hz, 1C), 102.96 (d, J = 22.8 Hz, 
1C), 55.2, 50.5, 26.4; 19F NMR (CDCl3?? ?? ? -124.73 (sextet, J = 4.6 Hz, 1F). (TLC Rf 
70:30 ethyl acetate:hexanes = 0.48). FAB-HRMS m/z 337.1478 [M+H]+. 
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5-fluoro-3-(2-(4-(3-methoxyphenyl)-1H-1,2,3-triazol-1-yl)ethyl)-1H-indole (5b): 
 
973 mg (4.82 mmol) 3-(2-azidoethyl)-5-fluoro-1H-indole was dissolved in 8 mL 2:1 
PEG-400:DMF and 1.15 g CuI and 0.670 mL (5.30 mmol) 3-Ethynylanisole added. The 
mixture was stirred at room temperature for 12 h. The mixture was diluted with 60 mL 
H2O and extracted with 3x 40 mL portions of ethyl acetate. The organic layers were 
combined, dried over Na2SO4, decanted and the solvent removed by rotary evaporation. 
The crude was purified by flash column chromatography, eluting with 70:30 ethyl 
acetate:hexanes to give 680 mg (42 % yield) of a light brown solid.  1H NMR (CDCl3?????
8.64 (br s, 1H), 7.47 (s, 1H), 7.33 (m, 1H), 7.24 (m, 3H), 7.14 (dd, J = 9.6 Hz, 2.5 Hz, 
1H), 6.90 (td, J = 9 Hz, 2.4 Hz, 1H), 6.83 (m, 2H), 4.61 (t, J = 6.8 Hz, 2H), 3.77 (s, 3H), 
3.30 (t, J = 6.9 Hz, 2H); 13C NMR (CDCl3???????????????????????J = 235 Hz, 1C), 147.3, 
132.7, 131.7, 129.8, 127.08 (d, J = 9.2 Hz, 1C), 124.6, 120.4, 118.1, 114.1, 112.20 (d, J 
= 9.1 Hz, 1C), 110.90 (d, J = 4.6 Hz, 1C), 110.8, 110.51 (d, J = 26.0 Hz, 1C), 102.96 (d, 
J = 24.4 Hz, 1C), 55.2, 50.6, 26.4; 19F NMR (CDCl3?????-124.65 (sextet, J = 4.6 Hz, 1F). 
(TLC Rf 70:30 ethyl acetate:hexanes = 0.48). FAB-HRMS m/z 337.1457 [M+H]+. 
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3-(1-(2-(5-fluoro-1H-indol-3-yl)ethyl)-1H-1,2,3-triazol-4-yl)phenol (5c): 
 
973 mg (4.82 mmol) 3-(2-azidoethyl)-5-fluoro-1H-indole was dissolved in 8 mL 2:1 
PEG-400:DMF and 1.15 g CuI and 0.580 mL (5.30 mmol) 3-Hydroxyphenylacetylene 
added. The mixture was stirred at room temperature for 12 h. The mixture was diluted 
with 60 mL H2O and extracted with 3x 40 mL portions of ethyl acetate. The organic 
layers were combined, dried over Na2SO4, decanted and the solvent removed by rotary 
evaporation. The crude was purified by flash column chromatography, eluting with 70:30 
ethyl acetate:hexanes to give 620 mg (40 % yield) of a yellow powder.  1H NMR 
?????????????????????????????.48 (s, 1H), 8.46 (s, 1H), 7.30 (m, 2H), 7.19 (m, 4H), 6.87 
(td, J = 10.7 Hz, 2.4 Hz, 1H), 6.69 (m, 1H), 4.61 (t, J = 7.3 Hz, 2H), 3.26 (t, J = 7.1 Hz, 
2H); 13?????? ??????? ?? ? ??????? ??????? ???? J = 230.4 Hz, 1C), 146.9, 133.5, 132.8, 
130.6, 127.84 (d, J = 10.6 Hz, 1C), 126.1, 122.0, 116.6, 115.5, 113.02 (d, J = 10.8 Hz, 
1C), 112.5, 111.00 (d, J = 5.9 Hz, 1C), 109.85 (d, J = 26.0 Hz, 1C), 103.65 (d, J = 22.9 
Hz, 1C), 50.7, 26.4; 19?????? ??????? ?? ? -125.80 (sextet, J = 4.5 Hz, 1F). (TLC Rf 
70:30 ethyl acetate:hexanes = 0.43). FAB-HRMS m/z 323.1300 [M+H]+. 
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3-(2-(4-(3,5-dimethoxyphenyl)-1H-1,2,3-triazol-1-yl)ethyl)-5-fluoro-1H-indole (5d): 
 
1.42 g (6.94 mmol) 3-(2-azidoethyl)-5-fluoro-1H-indole was dissolved in 8 mL 2:1 PEG-
400:DMF and 1.16 g CuI and 1.35 g (8.32 mmol) 1-Ethynyl-3,5-dimethoxybenzene  
added. The mixture was stirred at room temperature for 12 h. The mixture was diluted 
with 60 mL H2O and extracted with 3x 40 mL portions of ethyl acetate. The organic 
layers were combined, dried over Na2SO4, decanted and the solvent removed by rotary 
evaporation. The crude was purified by dissolving the solid in hot ethyl acetate and 
reprecipitating by the addition of hexanes to give 700 mg (28 % yield) of a tan powder.  
1??????????????? ??????????????????????????? 1H), 7.30 (m, 2H), 7.14 (d, J = 2.5 Hz, 
1H), 6.94 (d, J = 2.3 Hz, 2H), 6.87 (td, J = 9.1 Hz, 2.6 Hz, 1H), 6.42 (t, J = 2.3 Hz, 1H), 
4.61 (t, J = 7.3 Hz, 2H), 3.75 (s, 6H), 3.26 (t, J = 7.2 Hz, 2H); 13????????????????
161.5, 158.47 (d, J = 230.4 Hz, 1C), 146.8, 133.44 (d, J = 4.6 Hz, 1C), 127.86 (d, J = 
10.7 Hz, 1C), 126.1, 122.5, 113.04 (d, J = 9.2 Hz, 1C), 110.95 (d, J = 4.6 Hz, 1C), 
109.87 (d, J = 25.9 Hz, 1C), 103.7, 103.5, 100.5, 55.9, 50.8, 26.4. 19????????????????-
125.83 (sextet, J = 4.5 Hz, 1F). (TLC Rf 70:30 ethyl acetate:hexanes = 0.42). FAB-
HRMS m/z 367.1563 [M+H]+. 
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5-fluoro-3-(2-(4-(4-fluorophenyl)-1H-1,2,3-triazol-1-yl)ethyl)-1H-indole (5e): 
 
1.42 g (6.94 mmol) 3-(2-azidoethyl)-5-fluoro-1H-indole was dissolved in 8 mL 2:1 PEG-
400:DMF and 1.16 g CuI and 0.955 mL (8.32 mmol) 1-Ethynyl-4-fluorobenzene added. 
The mixture was stirred at room temperature for 12 h. The mixture was diluted with 60 
mL H2O and extracted with 3x 40 mL portions of ethyl acetate. The organic layers were 
combined, dried over Na2SO4, decanted and the solvent removed by rotary evaporation. 
The crude was purified by flash column chromatography, eluting with 70:30 ethyl 
acetate:hexanes to give 500 mg (22% yield) of a light yellow solid.  1H NMR (CDCl3?????
8.20 (br s, 1H), 7.68 (m, 2H), 7.42 (s, 1H), 7.25 (m, 1H), 7.17 (dd, J = 9.5 Hz, 2.5 Hz, 
1H), 7.06 (m, 2H), 6.94 (td, J = 8.8 Hz, 2.4 Hz, 1H), 6.87 (d, J = 2.2 Hz, 1H), 7.65 (t, J = 
6.2 Hz, 2H), 3.35 (t, J = 6.9 Hz, 2H); 13C NMR (CDCl3???????????????J = 247.2 Hz, 1C), 
158.1 (d, J = 235.0 Hz, 1C), 146.8, 132.9, 127.6 (d, J = 7.7 Hz, 1C), 127.4 (d, J = 10.7 
Hz, 1C), 127.0 (d, J = 3.1 Hz, 1C), 124.7, 120.0, 116.0 (d, J = 21.4 Hz, 1C), 112.4 (d, J 
= 9.2 Hz, 1C), 111.5 (d, J = 4.6 Hz, 1C), 111.0 (d, J = 25.9 Hz, 1C), 103.4 (d, J = 22.9 
Hz, 1C), 50.8, 26.7 . 19F NMR (CDCl3?? ?? ? -114.04 (septet, J = 4.6 Hz, 1F), -124.48 
(sextet, J = 4.4 Hz, 1F). (TLC Rf 70:30 ethyl acetate:hexanes = 0.5). FAB-HRMS m/z 
325.1254 [M+H]+. 
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3-(2-(4-(3,5-dimethoxyphenyl)-1H-1,2,3-triazol-1-yl)ethyl)-1H-indol-5-ol (6a): 
 
1.62 g (8.1 mmol) 3-(2-azidoethyl)-1H-indol-5-ol was dissolved in 8 mL 2:1 PEG-
400:DMF and 1.16 g CuI and 1.53 g (8.9 mmol) 1-Ethynyl-3,5-dimethoxybenzene added. 
The mixture was stirred at room temperature for 12 h. The mixture was added to 40 mL 
H2O and extracted with 3x 40 mL portions of ethyl acetate. The organic layers were 
combined, dried over Na2SO4, decanted and the solvent removed by rotary evaporation. 
The crude was purified by flash column chromatography, eluting with 70:30 ethyl 
acetate:hexanes to give 940 mg (32 % yield) of an off-white powder. Residual DMF was 
removed by heating to 90 °C and removing in vacuo.  1H NMR (CDCl3???? ?????????????
1H), 7.35 (s, 1H), 7.17 (d, 8.7 Hz, 1H), 6.94 (m, 1H), 6.87 (m, 2H), 6.78 (m, 2H), 6.38 (t, 
J = 2.3 Hz, 1H), 6.10 (br s, 1H), 4.56 (t, J = 6.8 Hz, 2H), 3.76 (s, 6H), 3.25 (t, J = 7.1 
Hz, 2H); 13C NMR (CDCl3?? ?? ? ??????? ??????? ??????? ??????? ??????? ??????? ??????? ???????
112.4, 112.1, 110.4, 103.7, 102.8, 100.5, 55.4, 50.8, 26.6. (TLC Rf 70:30 EtoAc:hexanes 
= 0.30). FAB-HRMS m/z 365.1595 [M+H]+. 
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3-(2-(4-(3-methoxyphenyl)-1H-1,2,3-triazol-1-yl)ethyl)-1H-indol-5-ol (6b): 
 
1.18 g (5.86 mmol) 3-(2-azidoethyl)-1H-indol-5-ol was dissolved in 8 mL 2:1 PEG-
400:DMF and 1.15 g CuI and 0.815 mL (6.45 mmol) 3-Ethynylanisole added. The 
mixture was stirred at room temperature for 12 h. The mixture was added to 40 mL H2O 
and extracted with 3x 40 mL portions of ethyl acetate. The organic layers were combined, 
dried over Na2SO4, decanted and the solvent removed by rotary evaporation. The crude 
was purified by flash column chromatography, eluting with 70:30 ethyl acetate:hexanes 
to give 680 mg (35 % yield) of an off-white powder. Residual DMF was removed by 
heating to 70 °C and removing in vacuo.  1??????????????????????????????????????????
1H), 8.53 (s, 1H), 7.32 (m, 3H), 7.09 (d, J = 8.7 Hz, 1H), 6.95 (d, J = 2.4 Hz, 1H), 6.85 
(m, 2H), 6.57 (dd, J = 8.7 Hz, 2.3 Hz, 1H), 4.59 (t, J = 7.2 Hz, 2H), 3.76 (s, 3H), 3.20 (t, 
J = 7.2 Hz, 2H); 13?????????????????????????????????????????????????????????????????
124.3, 122.2, 118.1, 114.2, 112.5, 112.1, 111.0, 109.6, 102.7, 55.8, 50.7, 26.6. (TLC Rf 
70:30 EtoAc:hexanes = 0.33). FAB-HRMS m/z 335.1497 [M+H]+. 
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3-(2-(4-(4-methoxyphenyl)-1H-1,2,3-triazol-1-yl)ethyl)-1H-indol-5-ol (6c): 
 
1.74 g (8.61 mmol) 3-(2-azidoethyl)-1H-indol-5-ol was dissolved in 8 mL 2:1 PEG-
400:DMF and 1.16 g CuI and 1.23 mL (9.48 mmol) 4-Ethynylanisole added. The mixture 
was stirred under nitrogen at room temperature for 12 h. The mixture was diluted with 60 
mL H2O and extracted with 3x 40 mL portions of ethyl acetate. The organic layers were 
combined, dried over Na2SO4, decanted and the solvent removed by rotary evaporation. 
The crude was purified by partially solvating the solid in hot ethyl acetate and vacuum 
filtration to give 870 mg (30 % yield) of tan crystals.  1?????????????????????????????
1H), 8.62 (s, 1H), 8.41 (s, 1H), 7.71 (m, 2H), 7.11 (d, J = 8.6 Hz, 1H), 6.96 (m, 3H), 6.88 
(d, J = 2.3 Hz, 1H), 6.60 (dd, J = 8.5 Hz, 2.3 Hz, 1H), 4.59 (t, J = 7.3 Hz, 2H), 3.74 (s, 
3H), 3.21 (t, J = 7.5 Hz, 2H); 13C NMR (DMSO???? ????????????????????????????????????
127.1, 124.3, 124.2, 121.0, 115.0, 112.5, 112.2, 109.7, 102.8, 55.8, 50.6, 26.7. (TLC Rf 
70:30 EtoAc:hexanes = 0.49). FAB-HRMS m/z 335.1512 [M+H]+. 
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3-(2-(4-(4-fluorophenyl)-1H-1,2,3-triazol-1-yl)ethyl)-1H-indol-5-ol (6d): 
 
1.70 g (8.42 mmol) 3-(2-azidoethyl)-1H-indol-5-ol was dissolved in 8 mL 2:1 PEG-
400:DMF and 1.16 g CuI and 1.10 mL (9.61 mmol) 1-Ethynyl-4-fluorobenzene added. 
The mixture was stirred at room temperature for 12 h under nitrogen. The mixture was 
diluted with 60 mL H2O and extracted with 3x 40 mL portions of ethyl acetate. The 
organic layers were combined, dried over Na2SO4, decanted and the solvent removed by 
rotary evaporation. The crude was washed with 40 mL of 70:30 ethyl acetate:hexanes and 
collected by vacuum filtration to give 1.0 g (37 % yield) of tan crystals.  1H NMR 
????????????????????????????????????????????????????????????????????????????????J = 8.9 Hz, 
2.2 Hz, 2H), 7.12 (d, J = 8.7 Hz, 1H), 6.97 (d, J = 2.4 Hz, 1H), 6.89 (d, J = 2.3 Hz, 1H), 
6.61 (dd, J = 8.5 Hz, 2.3 Hz, 1H) 4.62(t, J = 7.2 Hz, 2H), 3.21 (t, J = 7.3 Hz, 2H); 13C 
?????????????????????????J = 244.2 Hz, 1C), 151.10, 146.00, 131.43, 128.30, 128.16 
(d, J = 3.0 Hz, 1C), 127.77 (d, J = 7.6 Hz, 1C), 124.30, 121.90, 116.45 (d, J = 21.3 Hz, 
1C), 112.50, 112.20, 109.60, 102.80, 50.72, 26.70. 19????????????????-114.65 (septet, 
J = 4.6 Hz, 1F). FAB-HRMS m/z 323.1314 [M+H]+. 
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3-(2-(4-(3-hydroxyphenyl)-1H-1,2,3-triazol-1-yl)ethyl)-1H-indol-5-ol (6e): 
 
1.70 g (8.41 mmol) 3-(2-azidoethyl)-1H-indol-5-ol was dissolved in 8 mL 2:1 PEG-
400:DMF and 1.16 g CuI and 1.03 mL (9.47 mmol) 3-Hydroxyphenylacetylene added. 
The mixture was stirred under nitrogen at room temperature for 12 h. The mixture was 
diluted with 60 mL H2O and extracted with 3x 40 mL portions of ethyl acetate. The 
organic layers were combined, dried over Na2SO4, decanted and the solvent removed by 
rotary evaporation. The crude was purified by flash column chromatography, eluting with 
70:30 ethyl acetate:hexanes to give 960 mg (36 % yield) as a brown solid. Residual 
solvent and DMF was removed in vacuo at 60 °C  1??????????????????????????????????
9.51 (s, 1H), 8.63 (s, 1H), 8.45 (s, 1H), 7.25 (m, 1H), 7.19 (m, 2H), 7.13 (d, J = 8.5 Hz, 
1H), 6.96 (d, J = 2.4 Hz, 1H), 6.90 (d, J = 2.3 Hz, 1H), 6.71 (m 1H), 6.62 (dd, J = 8.7 
Hz, 2.3 Hz, 1H), 4.61 (t, J = 7.3 Hz, 2H), 3.22 (t, J = 7.3 Hz, 2H); 13????????????????
158.4, 151.1, 146.9, 132.8, 131.4, 130.6, 128.3, 124.3, 121.9, 116.7, 115.5, 112.53, 
112.47, 112.2, 109.6, 102.8, 50.6, 26.7. (TLC Rf 70:30 EtoAc:hexanes = 0.20). FAB-
HRMS m/z 321.1348 [M+H]+. 
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3-(2-(4-(3,5-dimethoxyphenyl)-1H-1,2,3-triazol-1-yl)ethyl)-5-methoxy-1H-indole 
(7a): 
 
1.11 g (5.14 mmol) 3-(2-azidoethyl)-5-methoxy-1H-indole was dissolved in 8 mL 2:1 
PEG-400:DMF and 1.15 g CuI and 920 mg (5.67 mmol) 1-Ethynyl-3,5-
dimethoxybenzene added. The mixture was stirred at room temperature for 12 h. The 
mixture was added to 40 mL H2O and extracted with 3x 40 mL portions of ethyl acetate. 
The organic layers were combined, dried over Na2SO4, decanted and the solvent removed 
by rotary evaporation. The crude was purified by flash column chromatography, eluting 
with 70:30 ethyl acetate:hexanes to give 670 mg (34 % yield) of a light brown solid. 
Residual DMF was removed by heating to 70 °C and removing in vacuo.  1H NMR 
(CDCl3?????????????????????????????????????????????J = 8.8 Hz, 1H), 6.88 (m, 3H), 6.80 (m, 
2H), 6.40 (t, J = 2.3 Hz, 1H), 4.59 (t, J = 6.8 Hz, 2H), 3.79 (s, 3H), 3.74 (s, 6H), 3.30 (t, 
J = 6.8 Hz, 2H); 13C NMR (CDCl3???? ?????????????????????????????????????????? 123.4, 
120.5, 112.1, 110.5, 103.5, 100.2, 99.8, 55.7, 55.2, 50.7, 26.3. (TLC Rf 70:30 
EtoAc:hexanes = 0.43). FAB-HRMS m/z 379.1787 [M+H]+. 
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5-methoxy-3-(2-(4-(3-methoxyphenyl)-1H-1,2,3-triazol-1-yl)ethyl)-1H-indole (7b): 
 
1.11 g (5.14 mmol) 3-(2-azidoethyl)-5-methoxy-1H-indole was dissolved in 8 mL 2:1 
PEG-400:DMF and 1.15 g CuI and 0.72 mL (5.67 mmol) 3-Ethynylanisole added. The 
mixture was stirred at room temperature for 12 h. The mixture was added to 60 mL H2O 
and extracted with 3x 40 mL portions of ethyl acetate. The organic layers were combined, 
dried over Na2SO4, decanted and the solvent removed by rotary evaporation. The crude 
was purified by flash column chromatography, eluting with 70:30 ethyl acetate:hexanes 
to give 1.37 g (77 % yield) of an orange oil. Residual DMF was removed by heating to 70 
°C and removing in vacuo.  1H NMR (CDCl3?????????????????????????????????????????????
1H), 7.21 (m, 3H), 6.90 (d, J = 2.3 Hz, 1H), 6.82 (m, 3H), 4.60 (t, J = 6.9 Hz, 2H), 3.79 
(s, 3H), 3.76 (s, 3H), 3.30 (t, J = 6.8 Hz, 2H); 13C NMR (CDCl3??????????????????????????
131.8, 131.3, 129.7, 127.1, 123.4, 120.4, 117.9, 113.9, 112.1, 110.7, 110.5, 99.6, 55.7, 
55.1, 50.7, 26.4. (TLC Rf 70:30 EtoAc:hexanes = 0.42). FAB-HRMS m/z 349.1653 
[M+H]+. 
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3-(1-(2-(5-methoxy-1H-indol-3-yl)ethyl)-1H-1,2,3-triazol-4-yl)phenol (7c): 
 
1.15 g (5.32 mmol) 3-(2-azidoethyl)-5-methoxy-1H-indole was dissolved in 8 mL 2:1 
PEG-400:DMF and 1.15 g CuI and 0.64 mL (5.85 mmol) 3-Hydroxyphenylacetylene 
added. The mixture was stirred at room temperature for 12 h. The mixture was added to 
60 mL H2O and extracted with 3x 40 mL portions of ethyl acetate. The organic layers 
were combined, dried over Na2SO4, decanted and the solvent removed by rotary 
evaporation. The crude was purified by flash column chromatography, eluting with 70:30 
ethyl acetate:hexanes to give 740  mg (42 % yield) of an off-white crystalline solid. 
Residual DMF was removed by heating to 70 °C and removing in vacuo.  1H NMR 
(CDCl3?????????????????????????????????????????????????????????????????????????????????????
(d, J = 2.5 Hz, 1H), 6.82 (m, 2H), 6.75 (d, J = 2.4 Hz, 1H), 4.62 (t, J = 6.9 Hz, 2H), 3.81 
(s, 3H), 3.32 (t, J = 6.4 Hz, 2H); 13C NMR (CDCl3??????????????????????????????6, 131.4, 
130.1, 127.2, 123.5, 120.6, 117.7, 115.6, 112.8, 112.5, 112.2, 110.8, 100.1, 56.0, 50.9, 
26.5. (TLC Rf 70:30 EtoAc:hexanes = 0.31). FAB-HRMS m/z 335.1513 [M+H]+. 
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5-methoxy-3-(2-(4-(4-methoxyphenyl)-1H-1,2,3-triazol-1-yl)ethyl)-1H-indole (7d): 
 
800 mg (4.21 mmol) 3-(2-azidoethyl)-5-methoxy-1H-indole was dissolved in 8 mL 2:1 
PEG-400:DMF and 1.12 g CuI and 0.59 mL (4.63 mmol) 4-Ethynylanisole added. The 
mixture was stirred at room temperature for 12 h. The mixture was added to 60 mL H2O 
and extracted with 3x 40 mL portions of ethyl acetate. The organic layers were combined, 
dried over Na2SO4, decanted and the solvent removed by rotary evaporation. The crude 
was purified by flash column chromatography, eluting with 70:30 ethyl acetate:hexanes 
to give 600 mg (41 % yield) of an orange oil. Residual DMF was removed by heating to 
70 °C and removing in vacuo.  1H NMR (CDCl3?????????????????????????????????????????????
1H), 7.2 (d, J = 8.8 Hz, 1H), 6.88 (m, 5H), 4.59 (t, J = 7.2 Hz, 2H), 3.78 (s, 3H), 3.76 (s, 
3H), 3.30 (t, J = 6.8 Hz, 2H) ; 13C NMR (CDCl3???? ????????????????????????????????????
126.8, 123.4, 123.2, 119.5, 114.1, 112.2, 110.6, 105.4, 99.9, 55.8, 55.1, 50.7, 26.4. (TLC 
Rf 70:30 EtoAc:hexanes = 0.33). FAB-HRMS m/z 349.1659 [M+H]+. 
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3-(2-(4-(4-fluorophenyl)-1H-1,2,3-triazol-1-yl)ethyl)-5-methoxy-1H-indole (7e): 
 
1.15 g (5.32 mmol) 3-(2-azidoethyl)-5-methoxy-1H-indole was dissolved in 8 mL 2:1 
PEG-400:DMF and 1.15 g CuI and 0.67 mL (5.85 mmol) 1-Ethynyl-4-fluorobenzene 
added. The mixture was stirred at room temperature for 12 h. The mixture was added to 
60 mL H2O and extracted with 3x 40 mL portions of ethyl acetate. The organic layers 
were combined, dried over Na2SO4, decanted and the solvent removed by rotary 
evaporation. The crude was purified by flash column chromatography, eluting with 70:30 
ethyl acetate:hexanes to give 560  mg (31 % yield) of light brown viscous oil. Residual 
DMF was removed by heating to 70 °C and removing in vacuo.  1H NMR (CDCl3?? ???
8.40 (br s, 1H), 7.63 (m, 2H), 7.39 (s, 1H), 7.21 (d, J = 8.7 Hz, 1H), 7.02 (m, 2H), 6.89 
(d, J = 2.3 Hz, 1H), 6.84 (dd, J = 8.7 Hz,  J = 2.4 Hz, 1H), 6.80 (d, J = 2.4 Hz, 1H), 4.62 
(t, J = 7.0 Hz, 2H), 3.80 (s, 3H), 3.33 (t, J = 6.7 Hz, 2H); 13C NMR (CDCl3????????????????
J = 247.2 Hz, 1C), 154.1, 146.4, 131.4, 127.29 (d, J = 9.2 Hz, 1C), 127.2, 126.72 (d, J = 
3.0 Hz, 1C), 123.4, 120.0, 115.68 (d, J = 21.4 Hz, 1C), 112.3, 112.2, 110.7, 100.0, 55.8, 
50.8, 26.5; 19F NMR (CDCl3?? ?? ? -113.98 (septet, J = 4.6 Hz, 1F). (TLC Rf 70:30 
EtoAc:hexanes = 0.36). FAB-HRMS m/z 337.1464 [M+H]+. 
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3-(2-(4-(4-fluorophenyl)-1H-1,2,3-triazol-1-yl)ethyl)-4-methoxy-1H-indole (8a): 
 
980 mg (4.54  mmol) 3-(2-azidoethyl)-4-methoxy-1H-indole, 1.15 g CuI and 570 μL 
(4.99  mmol) 1-Ethynyl-4-fluorobenzene 1.1 eq was added to  8 mL 2:1 PEG-400:DMF 
and the mixture stirred at room temperature overnight. The resulting solution was diluted 
with 60 ml H2O and extracted with 3x 40 mL portions of ethyl acetate. The organic layers 
were combined, dried over Na2SO4, decanted and the solvent removed by rotary 
evaporation. The crude was purified by flash column chromatography, eluting with 70:30 
ethyl acetate:hexanes to give 660  mg (43 % yield) of a brown solid. Residual DMF and 
solvent was removed by vacuum at 60 °C.  1H NMR (CDCl3???????????????????????????????
2H), 7.36 (s, 1H), 7.10 (t, J = 7.8 Hz, 1H), 7.04 (m, 2H), 6.96 (dd, J = 8.1 Hz, 1 Hz, 1H), 
6.65 (d, J = 2.3 Hz, 1H), 6.51 (d, J = 7.8 Hz, 1H), 4.71 (t, J = 6.9 Hz, 2H), 3.95 (s, 3H), 
3.43 (t, J = 6.8 Hz, 2H); 13C NMR (CDCl3) ?????????????J = 247.2 Hz, 2C), 154.3, 146.2, 
138.1, 127.3 (d, J = 7.6 Hz, 2C), 126.9 (d, J = 3.1 Hz, 2C), 123.0, 121.8, 119.9, 116.8, 
115.7 (d, J = 22.9 Hz, 2C), 111.4, 104.8, 99.4, 55.1, 52.1, 28.4; 19F NMR (CDCl3?????-
114.2 (pentet, J = 4.5 Hz, 1F). (TLC Rf 70:30 EtoAc:hexanes = 0.33). FAB-HRMS m/z 
336 [M+H]+. 
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4-methoxy-3-(2-(4-(4-methoxyphenyl)-1H-1,2,3-triazol-1-yl)ethyl)-1H-indole (8b): 
 
1.34 g (6.20  mmol) 3-(2-azidoethyl)-4-methoxy-1H-indole, 1.15 g CuI and 890 μL (6.85 
mmol) 4-ethynylanisole 1.1 eq was added to  8 mL 2:1 PEG-400:DMF and the mixture 
stirred at room temperature overnight. The resulting solution was diluted with 60 ml H2O 
and extracted with 3x 40 mL portions of ethyl acetate. The organic layers were combined, 
dried over Na2SO4, decanted and the solvent removed by rotary evaporation. The crude 
was purified by flash column chromatography, eluting with 70:30 ethyl acetate:hexanes 
to give 690  mg (32 % yield) of an orange solid. Residual DMF and solvent was removed 
by vacuum at 60 °C.  1H NMR (CDCl3????????????????????????????????J = 9.2 Hz, 2.8 Hz, 
2H), 7.34 (s, 1H), 7.10 (t, J = 8.1 Hz, 1H), 6.96 (d, J = 8.3 Hz, 1H), 6.90 (dt, J = 9.2 Hz, 
2.8 Hz, 2H), 6.63 (d, J = 2.5 Hz, 1H), 6.51 (d, J = 7.4 Hz, 1H), 4..68 (t, J = 7.0 Hz, 2H), 
3.94 (s, 3H), 3.79 (s, 3H), 3.43 (t, J = 7.0 Hz, 2H); 13C NMR (CDCl3???????????????????
146.9, 138.1, 126.8, 123.5, 122.9, 121.8, 119.3, 116.8, 114.1, 111.4, 104.8, 99.3, 55.2, 
55.1, 52.0, 28.4.(TLC Rf: 0.42). FAB-HRMS m/z 349.1659 [M+H]+. 
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3-(2-(4-(3,5-dimethoxyphenyl)-1H-1,2,3-triazol-1-yl)ethyl)-4-methoxy-1H-indole 
(8c): 
 
1.27 g (5.88  mmol) 3-(2-azidoethyl)-4-methoxy-1H-indole, 1.15 g CuI and 1.04 g (6.47  
mmol) 1-Ethynyl-3,5-Dimethoxybenzene 1.1 eq was added to  8 mL 2:1 PEG-400:DMF 
and the mixture stirred at room temperature for 48 h. The resulting solution was diluted 
with 60 ml H2O and extracted with 3x 40 mL portions of ethyl acetate. The organic layers 
were combined, dried over Na2SO4, decanted and the solvent removed by rotary 
evaporation. The crude was purified by flash column chromatography, eluting with 70:30 
ethyl acetate:hexanes to give 750  mg (34 % yield) of an amber solid. Residual DMF and 
solvent was removed by vacuum at 60 °C.  1H NMR (CDCl3???????????????????????????????
1H), 7.08 (t, J = 7.9 Hz, 1H), 6.94 (d, J = 8.2 Hz, 1H), 6.89 (d, J = 1.8 Hz, 2H), 6.65 (d, 
J = 2.1 Hz, 1H), 6.50 (d, J = 7.8 Hz, 1H), 6.40 (t, J = 1.7 Hz, 1H), 4.70 (t, J = 6.8 Hz, 
2H), 3.93 (s, 3H), 3.78, (s, 3H), 3.43 (t, J = 6.8 Hz, 2H); 13C NMR (CDCl3???? ????????
154.6, 147.2, 138.4, 132.9, 123.3, 122.1, 120.7, 117.0, 111.7, 105.1, 103.8, 100.6, 99.7, 
55.7, 55.4, 52.4, 28.7.(TLC Rf: 0.43). FAB-HRMS m/z 379.1777 [M+H]+. 
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4-methoxy-3-(2-(4-(3-methoxyphenyl)-1H-1,2,3-triazol-1-yl)ethyl)-1H-indole (8d): 
 
1.34 g (6.20  mmol) 3-(2-azidoethyl)-4-methoxy-1H-indole, 1.15 g CuI and 870  μL 
(6.85 mmol) 3-Ethynylanisole 1.1 eq was added to  8 mL 2:1 PEG-400:DMF and the 
mixture stirred at room temperature for 48 h. The resulting solution was diluted with 60 
ml H2O and extracted with 3x 40 mL portions of ethyl acetate. The organic layers were 
combined, dried over Na2SO4, decanted and the solvent removed by rotary evaporation. 
The crude was purified by flash column chromatography, eluting with 70:30 ethyl 
acetate:hexanes to give 440  mg (20 % yield) of a light orange viscous oil. Residual DMF 
and solvent was removed by vacuum at 60 °C.  1H NMR (CDCl3???????????????????????????
(s, 1H), 7.36 (m, 1H), 7.25 (m, 2H), 7.10 (t, J = 7.9 Hz, 1H), 6.95 (dd, J = 8.1 Hz, 1 Hz, 
1H), 6.84 (dt, J = 6.8 Hz, 2.6 Hz, 1H), 6.65 (d, J = 2.3 Hz, 1H), 6.51 (d, J = 7.5 Hz, 1H), 
4.70 (t, J = 7.0 Hz, 2H), 3.95 (s, 3H), 3.80 (s, 3H), 3.43 (t, J = 7.0 Hz, 2H); 13C NMR 
(CDCl3?? ?? ??????? ??????? ??????? ??????? ??????? ??????? ??????? ??????? ??????? ??????? ???????
113.9, 111.4, 110.6, 104.8, 99.4, 55.2, 55.1, 52.0, 28.4.(TLC Rf: 0.50). FAB-HRMS m/z 
349.1671 [M+H]+. 
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3-(1-(2-(4-methoxy-1H-indol-3-yl)ethyl)-1H-1,2,3-triazol-4-yl)phenol (8e): 
 
980 mg (4.54  mmol) 3-(2-azidoethyl)-4-methoxy-1H-indole, 1.15 g CuI and 540  μL 
(4.99  mmol) 3-Hydroxyphenylacetylene 1.1 eq was added to  8 mL 2:1 PEG-400:DMF 
and the mixture stirred at room temperature for 48 h. The resulting solution was diluted 
with 60 ml H2O and extracted with 3x 40 mL portions of ethyl acetate. The organic layers 
were combined, dried over Na2SO4, decanted and the solvent removed by rotary 
evaporation. The crude was purified by flash column chromatography, eluting with 70:30 
ethyl acetate:hexanes to give 550  mg (36 % yield) of a light orange solid. Residual DMF 
and solvent was removed by vacuum at 60 °C.  1H NMR (CDCl3??????????????????????????
(m, 1H), 7.30 (br s, 1H), 7.24 (s, 1H), 7.19 (t, J = 7.8 Hz, 1H), 7.10 (m, 2H), 6.93 (dd, J 
= 8.2 Hz, 1 Hz, 1H), 6.83 (ddd, J = 8.0 Hz, 2.4 Hz, 1.2 Hz, 1H), 6.57 (d, J = 2.2 Hz, 1H), 
6.51 (d, J = 7.5 Hz, 1H), 4.69 (t, J = 6.7 Hz, 2H), 6.94 (s, 3H), 3.42 (t, J = 6.9 Hz, 2H); 
13C NMR (CDCl3) ?????????????????????????????????????????????????????????????????????????
116.8, 115.5, 112.8, 111.4, 104.8, 99.6, 55.2, 52.1, 28.3. (TLC Rf: 0.34). FAB-HRMS 
m/z 334 [M+H]+. 
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5-bromo-3-(2-(4-(3-methoxyphenyl)-1H-1,2,3-triazol-1-yl)ethyl)-1H-indole (9a): 
 
810 mg (3.06 mmol) 3-(2-azidoethyl)-5-bromo-1H-indole was dissolved in 5 mL 2:1 
PEG-400:DMF and 1.28 g 2 eq. CuI and 500 μL (3.93 mmol) 3-ethynylanisole 1.3 eq. 
added and the mixture stirred at room temperature overnight. The resulting solution was 
diluted with 40 mL H2O and extracted with 3x 40 mL portions of ethyl acetate. The 
organic layers were combined, dried over Na2SO4, decanted and the solvent removed by 
rotary evaporation. The crude was purified by flash column chromatography, eluting with 
70:30 ethyl acetate:hexanes increasing to 100% ethyl acetate to give 560 mg (46 % yield) 
of a dark brown syrup. Residual DMF was removed by heating to 90 °C and removing in 
vacuo.  1H NMR (CDCl3???????????????????????????????????????????????????????????????????, 
4H), 6.80 (m, 2H), 4.51 (t, J = 5.8 Hz, 2H), 3.72 (s, 3H), 3.22 (t, J = 6.7 Hz, 2H); 13C 
NMR (CDCl3?? ?? ? ??????? ??????? ??????? ??????? ??????? ??????? ??????? ??????? ??????? ???????
118.4, 114.4, 113.3, 112.1, 111.1, 110.8, 55.5, 50.9, 26.6. (TLC Rf 70:30 EtoAc:hexanes 
= 0.22). FAB-HRMS m/z 397.0653 [M+H]+. 
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5-bromo-3-(2-(4-(4-methoxyphenyl)-1H-1,2,3-triazol-1-yl)ethyl)-1H-indole (9b): 
 
860 mg (3.24 mmol) 3-(2-azidoethyl)-5-bromo-1H-indole was dissolved in 10 mL DMF 
and 1.26 g 2 eq. CuI and 515 μL (1.04 mmol) 4-ethynylanisole 1.2 eq added and the 
mixture stirred at room temperature overnight. The resulting solution was diluted with 
160 ml H2O and 40 mL ethyl acetate and 3.5 g disodium EDTA added with stir at room 
temperature for 1.5 h. The mixture was extracted with 3x 40 mL portions of ethyl acetate. 
The organic layers were combined, dried over Na2SO4, decanted and the solvent removed 
by rotary evaporation. The crude was purified by flash column chromatography, eluting 
with 70:30 ethyl acetate:hexanes to 100 % ethyl acetate to give 720 mg (56 % yield) of a 
dark brown oil. Residual DMF and solvent was removed by vacuum at 90 °C.  1H NMR 
(CDCl3???????????????????????????????????????????????????????????????????J = 8.7 Hz, 2H), 
6.78 (s, 1H), 4.55 (t, J = 7.3 Hz, 2H), 3.79 (s, 3H), 3.25 (t, J = 7.2 Hz, 2H); 13C NMR 
(CDCl3???? ??????????????????????????????????????????????????????????????????????????.2, 
113.0, 112.6, 110.4, 55.2, 50.6, 26.2. FAB-HRMS m/z 397.0667 [M+H]+. 
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5-bromo-3-(2-(4-(3,5-dimethoxyphenyl)-1H-1,2,3-triazol-1-yl)ethyl)-1H-indole (9c): 
 
700 mg (2.64 mmol) 3-(2-azidoethyl)-5-bromo-1H-indole was dissolved in 6 mL 2:1 
PEG-400:DMF and 1.0 g 2 eq. CuI and 515 mg (3.17 mmol) 1-Ethynyl-3,5-
dimethoxybenzene added. The mixture was stirred at room temperature for 12 h. The 
mixture was added to 40 mL H2O and extracted with 3x 40 mL portions of ethyl acetate. 
The organic layers were combined, dried over Na2SO4, decanted and the solvent removed 
by rotary evaporation. The crude was purified by flash column chromatography, eluting 
with 70:30 ethyl acetate:hexanes to give 560 mg (50 % yield) of a light yellow powder. 
Residual DMF was removed by heating to 90 °C and removing in vacuo.  1H NMR 
???????????????????????????????????????????????J = 2.0 Hz, 1H), 7.27 (dd, J = 8.5 Hz, 0.5 
Hz, 1H), 7.14 (dd, J = 8.7 Hz, 1.8 Hz, 2H), 6.95 (d, J = 2.3 Hz, 2H), 6.42 (t, J = 2.3 Hz, 
1H), 4.6 (t, J = 7.1 Hz, 2H), 3.75 (s, 6H), 3.27 (apparent triplet, 2H); 13C NMR (DMSO) 
?? ?????????????????????????????????????????????????????????????????????????????????????
(TLC Rf 70:30 EtoAc:hexanes = 0.30). FAB-HRMS m/z 427.0757 [M+H]+. 
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5-bromo-3-(2-(4-(4-fluorophenyl)-1H-1,2,3-triazol-1-yl)ethyl)-1H-indole (9d): 
 
1.00 g (3.77 mmol) 3-(2-azidoethyl)-5-bromo-1H-indole was dissolved in 8 mL 2:1 PEG-
400:DMF and 1.00 g CuI and 0.70 mL (6.11 mmol), 1-Ethynyl-4-fluorobenzene added. 
The mixture was stirred at room temperature for 12 h. The mixture was diluted with 60 
mL H2O and extracted with 3x 40 mL portions of ethyl acetate. The organic layers were 
combined, dried over Na2SO4, decanted and the solvent removed by rotary evaporation. 
The crude product was purified by flash column chromatography, eluting with 70:30 
ethyl acetate: hexanes and residual crude purified by reprecipitation. The crude solid was 
dissolved in acetone and the product precipitated by the addition of H2O. The purified 
product was collected by vacuum filtration to give 370 mg (25 % yield) combined of an 
off-white solid.  1H N???????????????????????????????????????????????????????????????????
J = 2.0 Hz, 1H), 7.23 (m, 3H), 7.14 (d, J = 2.0 Hz, 1H), 7.12 (m, 1H), 4.62 (t, J = 7.2 Hz, 
2H), 3.28 (t, J = 7.2 Hz, 2H); 13???????????????????????????J = 244.1 Hz, 1C), 146.0, 
135.5, 129.5, 128.1 (d, J = 4.2 Hz, 1C), 127.8 (d, J = 9.1 Hz, 1C), 125.7, 124.2, 121.9, 
121.2, 116.4 (d, J = 21.4 Hz, 1C), 114.1, 111.9, 110.6, 50.9, 26.3; 19????????????????
(septet, J = 4.5 Hz, 1F) -114.65. FAB-HRMS m/z 385.0461 [M+H]+. 
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3-(1-(2-(5-bromo-1H-indol-3-yl)ethyl)-1H-1,2,3-triazol-4-yl)phenol (9e): 
 
1.26 g (4.75  mmol) 3-(2-azidoethyl)-5-bromo-1H-indole was dissolved in 8 mL 2:1 
PEG-400:DMF and 1.15 g CuI and 570 μL (5.23 mmol) 3-Hydroxyphenylacetylene 
added and the mixture stirred at room temperature overnight. The resulting solution was 
diluted with 60 mL H2O and extracted with 3x 40 mL portions of ethyl acetate. The 
organic layers were combined, dried over Na2SO4, decanted and the solvent removed by 
rotary evaporation. The crude was purified by flash column chromatography, eluting with 
70:30 ethyl acetate:hexanes to give 800 mg (44 % yield) of a thick amber syrup. Residual 
DMF was removed by heating to 60 °C and removing in vacuo.  1H NMR (Acetone-???????
10.28 (br s, 1H), 8.50 (s, 1H), 8.20 (s, 1H), 7.78 (d, J = 1.8 Hz, 1H), 7.39 (m, 1H), 7.36 
(dd, J = 7.2 Hz, 0.7 Hz, 1H), 7.28 (dt, J = 7.6 Hz, 1.2 Hz, 1H), 7.21 (m, 2H), 7.15 (d, J = 
2.5 Hz, 1H), 6.78 (ddd, J = 8.1 Hz, 2.6 Hz, 1.1 Hz, 1H), 4.73 (t, J = 7.1 Hz, 2H), 3.41 (t, 
J = 7.2 Hz, 2H); 13C NMR (Acetone-???? ?? ? ??????? ??????? ??????? ??????? ??????? ???????
155.1, 124.3, 121.0, 120.9, 116.9, 114.9, 113.5, 112.4, 112.0, 110.9, 50.6, 26.2. (TLC Rf 
70:30 EtoAc:hexanes = 0.33). FAB-HRMS m/z 383.0501 [M+H]+. 
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3-(2-(4-(4-methoxyphenyl)-1H-1,2,3-triazol-1-yl)ethyl)-1H-indole (10a): 
 
1.21 g (6.51 mmol) 3-(2-azidoethyl)-1H-indole was dissolved in 6 mL 2:1 PEG-
400:DMF and 2.45 g 2 eq. CuI and 1.00 mL (7.81 mmol), 1.2 eq. 4-Ethynylanisole 
added. The mixture was stirred at room temperature for 12 h. The mixture was diluted 
with 60 mL H2O and extracted with 4x 40 mL portions of ethyl acetate. The organic 
layers were combined, dried over Na2SO4, decanted and the solvent removed by rotary 
evaporation. The crude was purified by flash column chromatography, eluting with 70:30 
ethyl acetate:hexanes to give 620 mg (30 % yield) of light brown powder. Residual DMF 
was removed by heating to 90 °C and removing in vacuo.  1H NMR (CDCl3??????????????
1H), 7.64 (d, J = 8.4 Hz, 2H), 7.57 (d, J = 7.7 Hz, 1H), 7.37 (m, 2H), 7.19 (apparent dt, 
2H), 6.90 (d, J = 8.4 Hz, 2H), 6.84 (d, J = 1.8 Hz, 1H), 4.67 (t, J = 7.0 Hz, 2H), 3.81 (s, 
3H), 3.39 (t, J = 7.1 Hz, 2H); 13C NMR (CDCl3???? ????????????????????????????????????
123.4, 122.7, 122.4, 119.7, 119.3, 118.2, 114.2, 111.4, 111.2, 55.3, 50.7, 26.6. (TLC Rf 
70:30 EtoAc:hexanes = 0.43). FAB-HRMS m/z 319.1559 [M+H]+. 
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3-(1-(2-(1H-indol-3-yl)ethyl)-1H-1,2,3-triazol-4-yl)phenol (10b): 
 
1.14 g (6.12 mmol) 3-(2-azidoethyl)-1H-indole was dissolved in 8 mL 2:1 PEG-
400:DMF and 1.15 g CuI and 0.752 mL (6.90 mmol), 3-Hydroxyphenylacetylene added. 
The mixture was stirred at room temperature for 12 h. The mixture was diluted with 60 
mL H2O and extracted with 3x 40 mL portions of ethyl acetate. The organic layers were 
combined, dried over Na2SO4, decanted and the solvent removed by rotary evaporation. 
The crude was purified by flash column chromatography, eluting with 70:30 ethyl 
acetate:hexanes to give 620 mg (54 % yield) of light brown powder. Residual DMF was 
removed by heating to 90 °C and removing in vacuo.  1?????????????????????????????
1H), 9.47 (s, 1H), 8.47 (s, 1H), 7.54 (d, J = 7.4 Hz, 1H), 7.30 (d, J = 8.1 Hz, 1H), 7.20 
(m 3H), 7.06 (m, 2H), 6.95 (t, J = 8.0 Hz, 1H), 6.67 (m, 1H), 4.62 (t, J = 7.5 Hz, 2H), 
3.28 (apparent t, 2H); 13?????? ??????? ?? ? ??????? ?46.9, 136.8, 132.8, 130.6, 127.6, 
123.9, 121.9, 121.8, 119.1, 118.8, 116.7, 115.5, 112.5, 112.1, 110.6, 50.8, 26.5. (TLC Rf 
70:30 EtoAc:hexanes = 0.38). FAB-HRMS m/z 305.1399 [M+H]+. 
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3-(2-(4-(3,5-dimethoxyphenyl)-1H-1,2,3-triazol-1-yl)ethyl)-1H-indole (10c): 
 
960 mg (5.16 mmol) 3-(2-azidoethyl)-1H-indole was dissolved in 6 mL 2:1 PEG-
400:DMF and 960 mg 2 eq. CuI and 1.00 g (6.19 mmol), 1.2 eq. 1-Ethynyl-3,5-
dimethoxybenzene added. The mixture was stirred at room temperature for 48 h. The 
mixture was added to 40 mL H2O and extracted with 3x 40 mL portions of ethyl acetate. 
The organic layers were combined, dried over Na2SO4, decanted and the solvent removed 
by rotary evaporation. The crude was purified by flash column chromatography, eluting 
with 70:30 ethyl acetate:hexanes to give 700 mg (39 % yield) of an off-white powder. 
Residual DMF was removed by heating to 90 °C and removing in vacuo.  1H NMR 
(CDCl3????????????????????????????J = 7.8 Hz, 1H), 7.40 (s, 1H), 7.34 (d, J = 7.2 Hz, 1H), 
7.18 (td, J = 8 Hz, 1.1 Hz, 1H), 7.13 (td, J = 7.8 Hz, 1.0 Hz, 1H), 6.89 (d, J = 2.3 Hz, 
2H), 6.80 (d, J = 2.3 Hz, 1H) 6.40 (t, J = 2.3 Hz, 1H), 4.64 (t, J = 7.1 Hz, 2H), 3.77 (s, 
6H), 3.36 (t, J = 6.9 Hz, 2H); 13C NMR (CDCl3???? ????????????????????????????????????
122.7, 122.2, 120.5, 119.6, 118.1, 111.5, 110.9, 103.6, 100.4, 55.4, 50.8, 26.5. (TLC Rf 
70:30 EtoAc:hexanes = 0.33). FAB-HRMS m/z 349.1659 [M+H]+. 
 
 
 
 
     
71 
 
3-(2-(4-(4-fluorophenyl)-1H-1,2,3-triazol-1-yl)ethyl)-1H-indole (10d): 
 
1.20 g (6.45mmol) 3-(2-azidoethyl)-1H-indole was dissolved in 8 mL 2:1 PEG-400:DMF 
and 1.25 g CuI and 0.800 mL (10.1 mmol), 1-Ethynyl-4-fluorobenzene added. The 
mixture was stirred at room temperature for 12 h. The mixture was diluted with 60 mL 
H2O and extracted with 3x 40 mL portions of ethyl acetate. The organic layers were 
combined, dried over Na2SO4, decanted and the solvent removed by rotary evaporation. 
The crude product was purified by reprecipitation by dissolving the solid in acetone and 
precipitating the product by the addition of H2O. The purified product was collected by 
vacuum filtration to give 650 mg (33 % yield) of an off-white cake.  1H NMR (CDCl3?????
8.06 (br s, 1H), 7.68 (m, 2H), 7.56 (d, J = 7.8 Hz, 1H), 7.36 (m 2H), 7.24 (apparent td, 
1H), 7.14 (td, J = 7.0 Hz, 1.0 Hz, 1H), 7.06 (td, J = 9.0 Hz, 0.6 Hz, 2H), 6.85 (d, J = 1.8 
Hz, 1H), 4.69 (t, J = 7.0 Hz, 2H), 3.40 (t, J = 7.0 Hz, 2H); 13C NMR (CDCl3???????????????
J = 244.2 Hz, 1C), 146.0, 136.8, 128.2 (d, J = 3.1 Hz, 1C), 127.8 (d, J = 9.1 Hz, 1C), 
127.6, 123.9, 121.9, 121.8, 119.1, 118.8, 116.5 (d, J = 21.4 Hz, 1C), 112.1, 110.6, 50.9, 
26.5; 19F NMR (CDCl3?? ?? ? -114.2 (septet, J = 4.6 Hz, 1F). FAB-HRMS m/z 307.1364 
[M+H]+. 
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3-(2-(4-(3-methoxyphenyl)-1H-1,2,3-triazol-1-yl)ethyl)-1H-indole (10e): 
 
1.15 g (6.18 mmol) 3-(2-azidoethyl)-1H-indole was dissolved in 6 mL 2:1 PEG-
400:DMF and 2.35 g 2 eq. CuI and 0.940 mL  (7.42 mmol), 1.2 eq. 3-Ethynylanisole 
added. The mixture was stirred at room temperature for 12 h. The mixture was added to 
40 mL H2O and extracted with 3x 40 mL portions of ethyl acetate. The organic layers 
were combined, dried over Na2SO4, decanted and the solvent removed by rotary 
evaporation. The crude was purified by flash column chromatography, eluting with 70:30 
ethyl acetate:hexanes to give 710 mg (36 % yield) of a viscous maroon oil. Residual 
DMF was removed by heating to 90 °C and removing in vacuo.  1H NMR (CDCl3?? ???
8.40 (s, 1H), 7.56 (d, J = 7.6 Hz, 1H), 7.42 (s, 1H), 7.26 (m, 7H), 6.84 (m, 2H), 4.66 (t, J 
= 6.8 Hz, 2H), 3.81 (s, 3H), 3.38 (t, J = 7.2 Hz, 2H); 13C NMR (CDCl3???????????????????
136.5, 132.2, 130.0, 127.0, 123.0, 122.5, 120.6, 119.9, 118.4, 118.3, 114.3, 111.7, 111.3, 
111.0, 55.5, 51.0, 27.0. FAB-HRMS m/z [M+H]+. 
 
3.6 Determination of antioxidant activity in linoleic acid emulsion 
system by ferric-thiocyanate method: 
 The total antioxidant activity of the newly synthesized melatonin/phenolic 
analogues was determined and compared to a known antioxidant butylated 
hydroxyanisole, by the ferric-thiocyanate method from a previously published procedure, 
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with some modifications.20,57,58 Different concentrations of sample (500 μL) (125, 62.5, 
32 μM) in DMSO were mixed with linoleic acid emulsion in potassium phosphate buffer 
(500 μL) (0.02 M, pH 7.0). Ten milliliters of linoleic acid emulsion was prepared by 
homogenous mixing of 35 mg Tween 20, 31 μL linoleic acid and 0.02 M phosphate 
buffer. The mixture was incubated in a warm water bath at 37 °C for 24 h. Aliquots of 0.1 
mL were taken at 24 h. and sequentially added to ethanol (5 mL, 75% v/v), ammonium 
thiocyanate (0.1 mL, 30% w/v) and ferrous chloride (0.1 mL, 0.02 M in 3.5% HCl v/v) to 
a sample solution (0.1 mL) and the absorbance read at 500 nm. Ethanol was used as a 
blank. The amount of oxidation was measured and the data reported are the average of 
triplicates. During the incubation time, peroxides are formed from the linoleic acid that 
leads to the oxidation of Fe2+ to Fe3+. The ferric ion complexes with thiocyanate, forming 
a red hue and this complex has a maximum absorbance at 500 nm.  The inhibition of lipid 
peroxidation in percent can be calculated from the following equation: 
LPI (%) = 100 – [(A1/A0) x 100], 
where A1 is the absorbance at 500 nm of the sample and A0 is the absorbance of the 
control at 500 nm.  
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Appendix-I 1H NMR Spectra 
 
Figure A-I.1. 1H NMR spectra of (5a)
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Figure A-I.2. 1H NMR spectra of (5b) 
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Figure A-I.3. 1H NMR spectra of (5c) 
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Figure A-I.4. 1H NMR spectra of (5d) 
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Figure A-I.5. 1H NMR spectra of (5e) 
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Figure A-I.6. 1H NMR spectra of (6a) 
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Figure A-I.7. 1H NMR spectra of (6b) 
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Figure A-I.8. 1H NMR spectra of (6c) 
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Figure A-I.9. 1H NMR spectra of (6d) 
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Figure A-I.10. 1H NMR spectra of (6e) 
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Figure A-I.11. 1H NMR spectra of (7a) 
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Figure A-1.12. 1H NMR spectra of (7b) 
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Figure A-I.13. 1H NMR spectra of (7c) 
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Figure A-I.14. 1H NMR spectra of (7d) 
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Figure A-I.15. 1H NMR spectra of (7e) 
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Figure A-I.16. 1H NMR spectra of (8a) 
 
 
 
 
-1
. 0
- 0
. 5
0
. 0
0
. 5
1
. 0
1
. 5
2
. 0
2
. 5
3
. 0
3
. 5
4
. 0
4
. 5
5
. 0
5
. 5
6
. 0
6
. 5
7
. 0
7
. 5
8
. 0
8
. 5
9
. 0
9
. 5
10
. 5
f1
 
(p
pm
)
- 5
00
0
050
00
10
00
0
15
00
0
20
00
0
25
00
0
30
00
0
35
00
0
40
00
0
45
00
0
50
00
0
55
00
0
60
00
0
65
00
0
     
93 
 
 
Figure A-I.17. 1H NMR spectra of (8b) 
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Figure A-I.18. 1H NMR spectra of (8c) 
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Figure A-I.19. 1H NMR spectra of (8d) 
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Figure A-I.20. 1H NMR spectra of (8e) 
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Figure A-I.21. 1H NMR spectra of (9a) 
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Figure A-I.22. 1H NMR spectra of (9b) 
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Figure A-I.23. 1H NMR spectra of (9c) 
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Figure A-I.24. 1H NMR spectra of (9d) 
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Figure A-I.25. 1H NMR spectra of (9e) 
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Figure A-I.26. 1H NMR spectra of (10a) 
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Figure A-I.27. 1H NMR spectra of (10b) 
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Figure A-I.28. 1H NMR spectra of (10c) 
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Figure A-I.29. 1H NMR spectra of (10d) 
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Figure A-I.30. 1H NMR spectra of (10e) 
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Appendix-II 13C NMR Spectra 
Figure A-II.1. 13C NMR spectra of (5a) 
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Figure A-II.2. 13C NMR spectra of (5b) 
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Figure A-II.3. 13C NMR spectra of (5c) 
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Figure A-II.4. 13C NMR spectra of (5d) 
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Figure A-II.5. 13C NMR spectra of (5e) 
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Figure A-II.6. 13C NMR spectra of (6a) 
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Figure A-II.7. 13C NMR spectra of (6b) 
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Figure A-II.8. 13C NMR spectra of (6c) 
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Figure A-II.9. 13C NMR spectra of (6d) 
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Figure A-II.10. 13C NMR spectra of (6e) 
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Figure A-II.11. 13C NMR spectra of (7a) 
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Figure A-II.12. 13C NMR spectra of (7b) 
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Figure A-II.13. 13C NMR spectra of (7c) 
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Figure A-II.14. 13C NMR spectra of (7d) 
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Figure A-II.15. 13C NMR spectra of (7e) 
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Figure A-II.16. 13C NMR spectra of (8a) 
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Figure A-II.17. 13C NMR spectra of (8b) 
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Figure A-II.18. 13C NMR spectra of (8c) 
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Figure A-II.19. 13C NMR spectra of (8d) 
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Figure A-II.20. 13C NMR spectra of (8e) 
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Figure A-II.21. 13C NMR spectra of (9a) 
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Figure A-II.22. 13C NMR spectra of (9b) 
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Figure A-II.23. 13C NMR spectra of (9c) 
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Figure A-II.24. 13C NMR spectra of (9d) 
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Figure A-II.25. 13C NMR spectra of (9e) 
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Figure A-II.26. 13C NMR spectra of (10a) 
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Figure A-II.27. 13C NMR spectra of (10b) 
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Figure A-II.28. 13C NMR spectra of (10c) 
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Figure A-II.29. 13C NMR spectra of (10d) 
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Figure A-II.30. 13C NMR spectra of (10e) 
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Appendix-III 19F NMR Spectra 
Figure A-III.1. 19F NMR spectra of (5a) 
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Figure A-III.2. 19F NMR spectra of (5b) 
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Figure A-III.3. 19F NMR spectra of (5c) 
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Figure A-III.4. 19F NMR spectra of (5d) 
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Figure A-III.5. 19F NMR spectra of (5e) 
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Figure A-III.6. 19F NMR spectra of (6d) 
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Figure A-III.7. 19F NMR spectra of (7e) 
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Figure A-III.8. 19F NMR spectra of (8a) 
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Figure A-III.9. 19F NMR spectra of (9d) 
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Figure A-III.10. 19F NMR spectra of (10b) 
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